WO2003015766A1 - Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin - Google Patents

Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin Download PDF

Info

Publication number
WO2003015766A1
WO2003015766A1 PCT/EP2002/008824 EP0208824W WO03015766A1 WO 2003015766 A1 WO2003015766 A1 WO 2003015766A1 EP 0208824 W EP0208824 W EP 0208824W WO 03015766 A1 WO03015766 A1 WO 03015766A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
polyethylene glycol
wogonin
cosmetic
sensitive
Prior art date
Application number
PCT/EP2002/008824
Other languages
German (de)
French (fr)
Inventor
Stefan Gallinat
Ludger Kolbe
Christopher Mummert
Claudia Mundt
Ursula Wensorra
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2003015766A1 publication Critical patent/WO2003015766A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/006Antidandruff preparations

Definitions

  • wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and / or for skin protection in the case of sensitive, dry skin
  • the present invention relates to the use of the flavonoid wogonin (5,7-dihydroxy-8-methoxy-flavon) for the production of cosmetic or dermatological preparations for the treatment, care and prophylaxis of sensitive skin and / or for the treatment and prophylaxis of the symptoms of a negative change the physiological homeostasis of healthy skin.
  • the invention further relates to the use of wogonin and preparations containing wogonin for immune stimulation of the skin, advantageously also for immune stimulation in the sense of treating injured skin, in particular for treating wounds.
  • the invention relates to preparations with extremely low so-called "stinging potential”.
  • Sensitive skin affects an increasing number of adults and children. Sensitive skin is a combination of various symptoms, such as hyper-reactive and intolerant skin. But atopic skin can also be subsumed under it. These skin conditions are often not entirely correct by those affected , referred to as "allergic" skin. Although an allergic disease can lead to symptoms of sensitive skin, the appearance of "sensitive skin” is not limited to allergy sufferers.
  • the skin especially the epidermis, as a barrier organ of the human organism, is particularly exposed to external influences.
  • the skin represents an immunological organ, which as an immunocompetent peripheral compartment plays its own role in inductive, effective and regulative immune processes of the whole organism.
  • the epidermis is richly equipped with nerves and nerve end devices such as Father Pacini lamellar bodies, Merkel cell neurite complexes and free nerve endings for sensation of pain, cold, heat and itching.
  • nerves and nerve end devices such as Father Pacini lamellar bodies, Merkel cell neurite complexes and free nerve endings for sensation of pain, cold, heat and itching.
  • This "sensitive skin” differs fundamentally from “dry skin” with thickened and hardened hom layers.
  • Typical reactions of "stinging" to sensitive skin are reddening, tension and burning of the skin as well as itching.
  • Cutting phenomena can be regarded as disorders to be treated cosmetically.
  • severe itching especially severe itching in the case of atopy, can also be described as a more serious dermatological disorder.
  • Typical disturbing neurosensory phenomena associated with the terms "stinging” or “sensitive skin” are reddening of the skin, tingling, tingling, tension and burning of the skin and itching.
  • PJFrosch and AMKligman describe a method for estimating the "stinging potential" of topically administered substances. Lactic acid and Pyruvic acid used. When measured using this method, however, amino acids, in particular glycine, were also found to be neurosensory active (such substances are called “Stinger").
  • Erythematous skin symptoms also occur as a side effect with certain skin diseases or irregularities. For example, the typical rash in the appearance of acne is regularly more or less red.
  • active ingredients and preparations containing such active ingredients should be made available for the cosmetic and dermatological treatment and / or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses, but also the appearance of the "stinging".
  • active substances or preparations containing such active substances should be made available which can be used for immune stimulation of the skin, advantageously also for immune stimulation in the sense of the effect promoting wound healing.
  • the shortcomings of the prior art are eliminated by the use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions - including atopic eczema - and / or for skin protection for sensitive, determined dry skin.
  • Cosmetic or topical dermatological preparations with an effective wogonin content When using cosmetic or topical dermatological preparations with an effective wogonin content, an effective treatment, but also a prophylaxis of inflammatory skin conditions - including atopic eczema - is possible. Cosmetic or topical dermatological preparations with an effective wogonin content also serve, surprisingly, to soothe sensitive or irritated skin.
  • Wogonin occurs, for example, in the trunk and bark of Oroxylum indicum (from the Bignoniaceae family) and the root of Scutellaria rivalis (from the Lamiaceae family).
  • Wogonin is advantageously used in cosmetic or dermatological preparations, with a content of 0.0005-50.0% by weight, in particular 0.01-20.0% by weight, based on the total weight of the composition.
  • isoflavones are Daidzeaidn (4 ', 7-dihydroxy-isoflavone), as 7-O-glucoside Daidzin in soy flour; Genistein (4 ', 5,7-trihydroxy isoflavone) from soybeans and red clover; Prunetin (4 ', 5-dihydroxy-7-methoxy-isoflavone) from the bark of plum trees; Biochanin A (5,7-dihydroxy-4'-methoxy-isoflavone) from chickpeas, red clover and other clover th; Orobol (3 ', 4', 5,7-tetrahydroxy isoflavone); Santal (3 ', 4', 5-trihydroxy-7-methoxy-isoflavone) made from sandalwood, redwood and other woods; Pratense ⁇ n (3 ', 5,7-trihydroxy-4'-methoxyisoflavone) from fresh red or meadow clover.
  • the preparations according to the invention advantageously contain substances which absorb UV radiation in the UV-A and / or UV-B range, the total amount of filter substances, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic
  • 0.1 wt .-% to 30 wt .-% preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic
  • UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • Other advantageous UV-A filter substances are the phenylene-1,4-bis (2-benzimidazyl) -3,3 ''5,5'-tetrasulfonic acid
  • salts especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis sodium salt
  • 1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt
  • benzene-1,4-di (2-oxo-3-bomylidenemethyl-10-sulfonic acid) is also called benzene-1,4-di (2-oxo-3-bomylidenemethyl-10-sulfonic acid) and is characterized by the following structure:
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, ie filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives with the following structure:
  • R 1 , R 2 and R 3 are independently selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom. Particularly preferred are the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine (INCl: Aniso triazine , soft sold under the trade name Tinosorb® S from CIBA-Chemikalien GmbH), and the 4> 4, 4 '- (1,3 l 5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2-ethylhexyl ester), synonymous: 2 > 4,6-tris [anilino- (p-carbo-2'-ethyl-1 , -hexyloxy)] - 1,3,5-triazine (INCl: oct
  • UV filter substances which the structural motif
  • UV filter substances for the purposes of the present invention, for example the s-triazine derivatives described in European patent application EP 570 838 A1, the chemical structure of which is given by the generic formula
  • R represents a branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups,
  • X represents an oxygen atom or an NH group
  • Ri a branched or unbranched a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C r C 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl or aryl radical, optionally substituted by one or more G, -C 4 -
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10
  • R 2 represents a branched or unbranched C., - C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C, -C 4 alkyl groups, when X represents the NH group, and one branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C r C 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched CrC ⁇ alkyl radical, a C 5 -C 12 cycloalkyl or aryl radical, optionally substituted by one or more CC 4 -
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10 when X represents an oxygen atom.
  • a particularly advantageous UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
  • dioctylbutylamidotriazon IRCl: dioctylbutamidotriazone
  • UVASORB HEB trade name UVASORB HEB from Sigma 3V.
  • R 1 , R 2 and A- represent a wide variety of organic radicals.
  • Also advantageous for the purposes of the present invention are the 2,4-bis - ⁇ [4- (3-suIfonato) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine sodium salt, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) - 1,3,5-triazine, the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- [4- (2-methoxyethylcarboxyl) phenylamino] -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) - 2-hydroxy] phenyl ⁇ -6- [4-
  • An advantageous broadband filter for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) [INCl : Bisoctyltriazole], which is characterized by the chemical structural formula
  • Tinosorb® M is marked and is available under the trade name Tinosorb® M from CIBA Chemical GmbH.
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1, 3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula
  • the UV-B filters can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B filter substances are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester
  • esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
  • Advantageous water-soluble UV-B filter substances are e.g. B .:
  • ⁇ sulfonic acid derivatives of 3-benzylidene camphor such as.
  • a further light protection filter substance to be used advantageously according to the invention is ethylhexyi-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul ® N 539 and is distinguished by the following structure:
  • preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-camosine, L- Carnosine and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. carotene, ß-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urocanic acid
  • peptides such as D, L-carnosine, D-camosine, L- Carnosine and its derivatives (e.g. anserine)
  • thioredoxin glutathione, cystine, cystine, cystamine and their glycosyl- , N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (eg buthioninsulfoximines, homocysteine sulfoximine, buthioninsulfones, Penta-, hexa-, heptathioninsulfoximine) in very low tolerable doses (e.g.
  • ⁇ -hydroxy fatty acids palmitic acid, phytic acid, lactoferrin
  • ⁇ -hydroxy acids e.g. citric acid, Lactic acid, malic acid
  • humic acid e.g. citric acid, Lactic acid, malic acid
  • bile acid e.g. bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives eg ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives alanine diacetic acid, flavonoids , Polyphenols, catechins, vitamin C and derivatives (e.g.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • the prophylaxis or the cosmetic or dermatological treatment with the cosmetic or topical dermatological preparations with an effective content of wogonin is carried out in the usual way, namely in such a way that the cosmetic or topical dermatological preparations with an effective content of wogonin are applied to the affected skin areas becomes.
  • Wogonin can advantageously be incorporated into conventional cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O ⁇ / V) o- the oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.
  • W / O type water-in-oil
  • O oil-in-water
  • O oil-in-water-in-oil
  • Emulsions according to the invention in the sense of the present invention for example in the form of a Cream, a lotion, a cosmetic milk are advantageous and contain, for example, fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
  • the cosmetic preparations according to the invention can therefore contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic Formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic Formulation such as alcohols,
  • Medical topical compositions in the sense of the present invention generally contain one or more drugs in effective concentration.
  • drugs for the sake of simplicity, for a clear distinction between cosmetic and medical use and corresponding products, reference is made to the legal provisions of the Federal Republic of Germany (e.g. cosmetics regulation, food and drug law).
  • Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 O 3 ), cerium (e.g. Ce 2 O 3 ), mixed oxides of the corresponding metals, like mixtures of such oxides. Pigments based on TiO 2 are particularly preferred.
  • the inorganic pigments are in hydrophobic form, i.e. that they have been treated to be water-repellent on the surface.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
  • One such method is, for example, that the hydrophobic surface layer after a reaction
  • n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
  • hydrophobized pigments shown in analogy to DE-OS 33 14 742 are advantageous.
  • Advantageous TiO 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
  • Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention.
  • Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
  • hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OSO 3 2 ' , -SO 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon radicals.
  • Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups: Anionic surfactants,
  • Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
  • Non-ionic surfactants do not form ions in an aqueous medium.
  • acylglutamates for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
  • acyl peptides for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
  • sarcosinates for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
  • taurates for example sodium lauroyl taurate and sodium methyl cocoyftaurate
  • Acyl lactylates for example sodium lauroyl taurate and sodium methyl cocoyftaurate
  • carboxylic acids for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
  • ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
  • ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,
  • Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and dilaureth-4-phosphate
  • acyl isethionates e.g. Sodium / ammonium cocoyl isethionate
  • alkyl sulfonates for example sodium coconut monoglyceride sulfate, sodium C ⁇ 2-14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
  • Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
  • sulfuric acid esters such as
  • alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C 12-13 pareth sulfate,
  • Alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
  • Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
  • Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous.
  • the cationic surfactants used in the invention can be also preferably selected from the group of quaternary ammonium compounds, in particular benzene zyltrialkylammoniumchloride or bromides, such as Benzyldimethylstea- rylammoniumchlorid, also alkyltrialkylammonium, such as for example, cetyl trimethyl ammonium chloride or bromide, alkyldimethylhydroxyethylammonium chlorides or - bromides, dialkyldimethylammonium chlorides or bromides, alkylamidethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammonium salts are
  • acyl / dialkyl ethylenediamine for example sodium acyl amphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxypropyl sulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
  • N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • alkanolamides such as cocamides MEA / DEA / MIPA
  • amine oxides such as cocoamidopropylamine oxide
  • esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
  • ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterols, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated es lanolin, ethoxy lated / propoxylated polysiloxanes, propoxylated POE ethers and alkyl polyglycosides such as
  • the surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 95% by weight, based on the total weight of the preparations.
  • the lipid phase of the cosmetic or dermatological emulsions according to the invention can advantageously be selected from the following group of substances: mineral oils, mineral waxes
  • Oils such as triglycerides of capric or caprylic acid as well as natural oils such as e.g. Castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids; benzoates;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions of the present invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be chosen from the Group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethyl hexyl lauryl, 2-ethyl hexyl lauryl, octyl ethyl acetate, 2-ethyl hexyl laurate, , Erucylerucate and synthetic, semisynthetic and natural mixtures of such esters, for example jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12-15 -alkyl benzoate and isotridecyl isononanoate and mixtures of C 12-15 - benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • paraffin oil paraffin oil
  • squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
  • silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R., - R 4 (to say that the number of different radicals is not necessarily limited to up to 4), m can assume values from 2 - 200,000.
  • n can take values from 3/2 to 20. Fractional values for n take into account that odd numbers of siloxyl groups may be present in the cycle.
  • Cyclomethicone e.g. decamethylcyclopentasiloxane
  • silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
  • silicone oils of a similar constitution to the compounds described above, the organic side chains of which are derivatized, for example polyethoxylated and / or polypropoxylated.
  • these include, for example, polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl-dimethicone copolyol (and) polyglycery I-4-isostearate (and) hexyliaurate)
  • the aqueous phase of the preparations according to the invention advantageously advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethy- glycol monomethyl or monoethyl ether and analog products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide and aluminum silicates.
  • alcohols, diols or polyols of low C number and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glyco
  • Preparations according to the invention which are present as emulsions particularly advantageously contain one or more hydrocolloids.
  • These hydrocolloids can advantageously be selected from the group of the gums, polysaccharides, cellulose derivatives, phyllosilicates, polyacrylates and / or other polymers.
  • Preparations according to the invention which are present as hydrogels contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group.
  • Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, locust bean gum, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
  • derivatized gums such as e.g. Hydroxypropyl guar (Jaguar® HP 8).
  • polysaccharides and derivatives are e.g. Hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
  • cellulose derivatives are e.g. Methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
  • Layered silicates contain naturally occurring and synthetic clays such as Montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Vegegum®. These can be used as such or in a modified form such as e.g. Stearylalkonium hectorite.
  • silica gels can also advantageously be used.
  • the polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
  • the polymers include, for example, polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.
  • Preparations according to the invention in the form of emulsions contain one or more emulsifiers. These emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
  • the nonionic emulsifiers include a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates) b) ethoxylated fatty alcohols and fatty acids c) ethoxylated alcohol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycols e.g. Triton X)
  • the anionic emulsifiers include a) soaps (e.g. sodium stearate) b) fatty alcohol sulfates c) mono-, di- and trialkyiphosphonic acid esters and their ethoxylates
  • the cationic emulsifiers include a) quaternary ammonium compounds with a long-chain aliphatic radical, e.g. Distearyldimonium Chloride
  • amphoteric emulsifiers include a) alkylamininoalkane carboxylic acids b) betaines, sulfobetaines c) imidazoline derivatives
  • emulsifiers which include beeswax, wool wax, lecithin and sterols.
  • O / W emulsifiers can, for example, advantageously be selected from the group of the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example: the fatty alcohol ethoxylates the ethoxylated wool wax alcohols, the polyethylene glycol ethers of the general formula RO - (- CH 2 -CH 2 -O-) n -R ', the fatty acid ethoxylates of the general formula
  • RO - (- CH 2 -CH 2 -O-) n -CH 2 -COOH and n represent a number from 5 to 30, the polyoxyethylene sorbitol fatty acid esters, the alkyl ether sulfates of the general formula RO - (- CH 2 -CH 2 -O-) n -SO 3 -H of the fatty alcohol propoxylates of the general formula
  • the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5-15. 5, provided the O / W emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
  • fatty alcohol ethoxylates from the group of ethoxylated stearyl alcohols, cetyl alcohols, cetyl stearyl alcohols (cetearyl alcohols).
  • cetyl alcohols cetyl stearyl alcohols
  • cetearyl alcohols cetearyl alcohols
  • Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolureth-12).
  • the sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
  • Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soyasterol has also proven itself.
  • polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / caprinate 20, glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate / cocoat to choose.
  • sorbitan esters from the group consisting of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C.
  • Atoms diglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms, monoglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, diglycerine ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and / or unbranched Alkanecarboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms and sorbitan esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms.
  • W / O emulsifiers are glyceryl Glycerylmonoisostea- advice, stearate glyceryl monomyristate, Giycerylmonooleat, diglyceryl monostearate, Diglycerylmonoiso-, propylene glycol, propylene glycol monoisostearate, Propylenglycolmonocap- triacrylate, propylene glycol, nocaprylat sorbitan, sorbitan Sorbitanmo-, Sorbitanmonoisooleat, sucrose, cetyl alcohol, stearyl alcohol, Arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyceryl monocaprylate.

Abstract

Use of wogonin for the production of cosmetic or dermatological preparations for the treatment, care and prophylaxis of sensitive skin and/or for treatment and prophylaxis of symptoms of a negative change in the physiological homeostasis of healthy skin.

Description

Beschreibung description
Verwendung von Wogonin zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener HautUse of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and / or for skin protection in the case of sensitive, dry skin
Die vorliegende Erfindung betrifft die Verwendung des Flavonoids Wogonin (5,7-Dihydroxy- 8-Methoxy-Flavon) zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung, Pflege und Prophylaxe von sensibler Haut und/oder zur Behandlung und Prophylaxe der Symptome einer negativen Veränderung der physiologischen Homeostase der gesunden Haut.The present invention relates to the use of the flavonoid wogonin (5,7-dihydroxy-8-methoxy-flavon) for the production of cosmetic or dermatological preparations for the treatment, care and prophylaxis of sensitive skin and / or for the treatment and prophylaxis of the symptoms of a negative change the physiological homeostasis of healthy skin.
Ferner betrifft die Erfindung die Verwendung von Wogonin und Zubereitungen, Wogonin enthaltend, zur Immunstimulation der Haut, dabei vorteilhaft auch zur Immunstimulation im Sinne einer Behandlung der verletzten Haut, insbesondere zur Behandlung von Wunden.The invention further relates to the use of wogonin and preparations containing wogonin for immune stimulation of the skin, advantageously also for immune stimulation in the sense of treating injured skin, in particular for treating wounds.
Darüberhinaus betrifft die Erfindung Zubereitungen mit extrem niedrigem sogenanntem "Stinging Potential".Furthermore, the invention relates to preparations with extremely low so-called "stinging potential".
Das Problem „sensible Haut" betrifft eine wachsende Anzahl Erwachsenen und Kindern. Mit Sensibler Haut bezeichnet man eine Kombination verschiedener Symptome, wie hyperreaktive und intolerante Haut. Aber auch atopische Haut kann darunter subsummiert werden. Diese Hautzustände werden von den Betroffenen oftmals, nicht ganz korrekt, als „allergische" Haut bezeichnet. Obwohl eine allergische Erkrankung zu Symptomen der sensiblen Haut führen kann, ist die Erscheinung „sensible Haut" nicht auf Allergiker beschränkt.The problem of "sensitive skin" affects an increasing number of adults and children. Sensitive skin is a combination of various symptoms, such as hyper-reactive and intolerant skin. But atopic skin can also be subsumed under it. These skin conditions are often not entirely correct by those affected , referred to as "allergic" skin. Although an allergic disease can lead to symptoms of sensitive skin, the appearance of "sensitive skin" is not limited to allergy sufferers.
Die Haut, insbesondere die Epidermis, ist als Barriereorgan des menschlichen Organismus in besonderem Maße äußeren Einwirkungen unterworfen. Nach dem heutigen wissen- liehen Verständnis repräsentiert die Haut ein immunologisches Organ, das als immunkompetentes peripheres Kompartiment eine eigene Rolle in induktiven, effektiven und regulativen Immunprozessen des Gesamtorganismen spielt.The skin, especially the epidermis, as a barrier organ of the human organism, is particularly exposed to external influences. According to today's knowledge With understanding, the skin represents an immunological organ, which as an immunocompetent peripheral compartment plays its own role in inductive, effective and regulative immune processes of the whole organism.
Die Epidermis ist reich mit Nerven und Nervenendapparaten wie Vater-Pacini-Lamellenkör- pern, Merkel-Zell-Neuritenkomplexen und freien Nervenendigungen für Schmerz-, Kälte-, Wärmeempfindung und Juckreiz ausgestattet.The epidermis is richly equipped with nerves and nerve end devices such as Father Pacini lamellar bodies, Merkel cell neurite complexes and free nerve endings for sensation of pain, cold, heat and itching.
Bei Menschen mit sensibler, empfindlicher oder verletzlicher Haut kann ein mit "Stinging" (<engl.> "to sting" = verletzen, brennen, schmerzen) bezeichnetes neurosensorisches Phänomen beobachtet werden. Diese "sensible Haut" unterscheidet sich grundsätzlich von "trockener Haut" mit verdickten und verhärteten Homschichten.In people with sensitive, sensitive or vulnerable skin, a neurosensory phenomenon called "stinging" (<engl.> "To sting" = injure, burn, pain) can be observed. This "sensitive skin" differs fundamentally from "dry skin" with thickened and hardened hom layers.
Typische Reaktionen des "Stinging" bei sensibler Haut sind Rötung, Spannen und Brennen der Haut sowie Juckreiz.Typical reactions of "stinging" to sensitive skin are reddening, tension and burning of the skin as well as itching.
Als neurosensorisches Phänomen ist der Juckreiz bei atopischer Haut anzusehen, sowie Juckreiz bei Hauterkrankungen.Itching in atopic skin and itching in skin diseases are to be regarded as a neurosensory phenomenon.
"Stinging"-Phänomene können als kosmetisch zu behandelnde Störungen angesehen werden. Starker Juckreiz dagegen, insbesondere bei Atopie auftretendes starkes Hautjucken, kann auch als schwerwiegendere dermatologische Störung bezeichnet werden."Stinging" phenomena can be regarded as disorders to be treated cosmetically. On the other hand, severe itching, especially severe itching in the case of atopy, can also be described as a more serious dermatological disorder.
Typische, mit den Begriffen "Stinging" oder "empfindlicher Haut" in Verbindung gebrachte, störende neurosensorische Phänomene sind Hautrötung, Kribbeln, Prickeln, Spannen und Brennen der Haut und Juckreiz. Sie können durch stimulierende Umgebungsbedingungen z.B. Massage, Tensideinwirkung, Wettereinfluß wie Sonne, Kälte, Trockenheit, aber auch feuchte Wärme, Wärmestrahlung und UV-Strahlung, z.B. der Sonne, hervorgerufen werden.Typical disturbing neurosensory phenomena associated with the terms "stinging" or "sensitive skin" are reddening of the skin, tingling, tingling, tension and burning of the skin and itching. By stimulating environmental conditions e.g. Massage, surfactant, weather influences such as sun, cold, dryness, but also moist heat, heat radiation and UV radiation, e.g. the sun.
In "Journal of the Society of Cosmetic Chemists" 28, S. 97 - 209 (Mai 1977) beschreiben P.J.Frosch und A.M.Kligman eine Methode zur Abschätzung des "Stinging-Potentials" topisch verabreichter Substanzen. Als positive Substanzen werden hier z.B. Milchsäure und Brenztraubensäure eingesetzt. Bei Messung nach dieser Methode wurden aber auch Aminosäuren, insbesondere Glycin, als neurosensorisch aktiv ermittelt (solche Substanzen werden "Stinger" genannt).In "Journal of the Society of Cosmetic Chemists" 28, pp. 97-209 (May 1977), PJFrosch and AMKligman describe a method for estimating the "stinging potential" of topically administered substances. Lactic acid and Pyruvic acid used. When measured using this method, however, amino acids, in particular glycine, were also found to be neurosensory active (such substances are called "Stinger").
Nach bisherigen Erkenntnissen tritt eine derartige Empfindlichkeit gegenüber ganz bestimmten Substanzen individuell unterschiedlich auf. Dies bedeutet, eine Person, die bei Kontakt mit einer Substanz "Stingingeffekte" erlebt, wird sie mit hoher Wahrscheinlichkeit bei jedem weiteren Kontakt wiederholt erleben. Der Kontakt mit anderen "Stingem" kann aber ebensogut ohne jede Reaktion verlaufen.According to previous knowledge, such a sensitivity to very specific substances occurs individually in different ways. This means that a person who experiences "stinging effects" when in contact with a substance is very likely to experience it repeatedly with each subsequent contact. Contact with other "Stingem" can just as well be without any reaction.
Viele mehr oder weniger empfindliche Personen haben auch bei Verwendung mancher desodorierenden oder antitranspirierend wirkenden Zubereitungen unter erythematösen Hauterscheinungen zu leiden.Many more or less sensitive people also suffer from erythematous skin symptoms when using some deodorant or antiperspirant preparations.
Erythematöse Hauterscheinungen treten auch als Begleiterscheinungen bei gewissen Hauterkrankungen oder -Unregelmäßigkeiten auf. Beispielsweise ist der typische Hautausschlag beim Erscheinungsbild der Akne regelmäßig mehr oder weniger stark gerötet.Erythematous skin symptoms also occur as a side effect with certain skin diseases or irregularities. For example, the typical rash in the appearance of acne is regularly more or less red.
Es war also die Aufgabe der vorliegenden Erfindung, den Nachteilen des Standes der Technik abzuhelfen.It was therefore the object of the present invention to remedy the disadvantages of the prior art.
Insbesondere sollten Wirkstoffe und Zubereitungen, solche Wirkstoffe enthaltend, zur kosmetischen und dermatologischen Behandlung und/oder Prophylaxe erythematöser, entzündlicher, allergischer oder autoimmunreaktiver Erscheinungen, insbesondere Dermatosen, aber auch des Erscheinungsbildes des "Stingings" zur Verfügung gestellt werden.In particular, active ingredients and preparations containing such active ingredients should be made available for the cosmetic and dermatological treatment and / or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses, but also the appearance of the "stinging".
Ferner sollten solche Wirkstoffe, bzw. Zubereitungen, solche Wirkstoffe enthaltend, zur Verfügung gestellt werden, welche zur Immunstimulation der Haut, dabei vorteilhaft auch zur Immunstimulation im Sinne der die Wundheilung fördernden Wirkung, verwendet werden können.Furthermore, such active substances or preparations containing such active substances should be made available which can be used for immune stimulation of the skin, advantageously also for immune stimulation in the sense of the effect promoting wound healing.
Erfindungsgemäß werden die Übelstände des Standes der Technik beseitigt durch die Verwendung von Wogonin zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen - auch dem atopischen Ekzem - und/oder zum Hautschutz bei empfindlich determinierter trockener Haut.According to the invention, the shortcomings of the prior art are eliminated by the use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions - including atopic eczema - and / or for skin protection for sensitive, determined dry skin.
Bei Anwendung kosmetischer oder topischer dermatologischer Zubereitungen mit einem wirksamen Gehalt an Wogonin ist eine wirksame Behandlung, aber auch eine Prophylaxe von entzündlichen Hautzuständen - auch dem atopischen Ekzem möglich. Kosmetische oder topische dermatologische Zubereitungen mit einem wirksamen Gehalt an Wogonin dienen aber auch in überraschender Weise zur Beruhigung von empfindlicher oder gereizter Haut.When using cosmetic or topical dermatological preparations with an effective wogonin content, an effective treatment, but also a prophylaxis of inflammatory skin conditions - including atopic eczema - is possible. Cosmetic or topical dermatological preparations with an effective wogonin content also serve, surprisingly, to soothe sensitive or irritated skin.
Wogonin ist durch folgende Struktur gekennzeichnet:Wogonin is characterized by the following structure:
Figure imgf000005_0001
Figure imgf000005_0001
Wogonin kommt beispielsweise in Stamm und Borke von Oroxylum indicum (aus der Familie der Bignoniaceae) sowie der Wurzel von Scutellaria rivalis (aus der Familie der Lamiaceae) vor.Wogonin occurs, for example, in the trunk and bark of Oroxylum indicum (from the Bignoniaceae family) and the root of Scutellaria rivalis (from the Lamiaceae family).
Vorteilhaft wird Wogonin in kosmetischen oder dermatologischen Zubereitungen verwendet, einem Gehalt von 0,0005 - 50,0 Gew.-%, insbesondere 0,01 - 20,0 Gew.-%, entsprechend, bezogen auf das Gesamtgewicht der Zusammensetzung.Wogonin is advantageously used in cosmetic or dermatological preparations, with a content of 0.0005-50.0% by weight, in particular 0.01-20.0% by weight, based on the total weight of the composition.
Es ist erfindungsgemäß vorteilhaft, Wogonin zusammen mit Isoflavonen einzusetzen, insbesondere dadurch gekennzeichnet, daß ein oder mehrere Isoflavone zusammen mit Tectorigenin eingesetzt werden, einem Gehalt des oder der Isoflavone von 0,02 - 10,0 Gew.-%, bevorzugt 0,02 - 5,0 Gew.-%, besonders vorteilhaft 0,5 - 3,0 Gew.-%, entsprechend, jeweils bezogen auf das Gesamtgewicht der Zusammensetzung.It is advantageous according to the invention to use wogonin together with isoflavones, in particular characterized in that one or more isoflavones are used together with tectorigenin, a content of the isoflavones or isoflavones of 0.02-10.0% by weight, preferably 0.02%. 5.0% by weight, particularly advantageously 0.5-3.0% by weight, correspondingly, in each case based on the total weight of the composition.
Einige bekanntere Isoflavone sind Daidzeϊn (4',7-Dihydroxy-lsoflavon), als 7-O-Glucosid Daidzin in Sojamehl; Genistein (4',5,7-Trihydroxy-lsoflavon) aus Sojabohnen und Rotklee; Prunetin (4',5-Dihydroxy-7-methoxy-lsoflavon) aus der Rinde von Pflaumenbäumen; Biocha- nin A (5,7-Dihydroxy-4'-methoxy-lsoflavon) aus Kichererbsen, Rotklee und anderen Kleear- ten; Orobol (3',4',5,7-Tetrahydroxy-lsoflavon); Santal (3',4',5-Trihydroxy-7-methoxy-lsoflavon) aus Sandelholz, Rotholz und anderen Hölzern; Pratenseϊn (3',5,7-Trihydroxy-4'-methoxyiso- flavon) aus frischem Rot- oder Wiesenklee. Einige dieser in Kleearten und Leguminosen wie Luzerne vorkommenden Isoflavone zeigen Östrogenwirkung auf Weidetiere und können unter umständen zu Fortpflanzungsstörungen bei diesen führen.Some more well-known isoflavones are Daidzeaidn (4 ', 7-dihydroxy-isoflavone), as 7-O-glucoside Daidzin in soy flour; Genistein (4 ', 5,7-trihydroxy isoflavone) from soybeans and red clover; Prunetin (4 ', 5-dihydroxy-7-methoxy-isoflavone) from the bark of plum trees; Biochanin A (5,7-dihydroxy-4'-methoxy-isoflavone) from chickpeas, red clover and other clover th; Orobol (3 ', 4', 5,7-tetrahydroxy isoflavone); Santal (3 ', 4', 5-trihydroxy-7-methoxy-isoflavone) made from sandalwood, redwood and other woods; Pratenseϊn (3 ', 5,7-trihydroxy-4'-methoxyisoflavone) from fresh red or meadow clover. Some of these isoflavones found in clover and legumes such as alfalfa show estrogen effects on grazing animals and can possibly lead to reproductive disorders in these.
Im folgenden sind Substitutionsschemata einiger natürlich vorkommender Isoflavone aufgeführt:The substitution schemes for some naturally occurring isoflavones are listed below:
Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000006_0001
Figure imgf000006_0002
Die Zubereitungen gemäß der Erfindung enthalten vorteilhaft Substanzen, die UV-Strahlung im UV-A- und/oder UV-B-Bereich absorbieren, wobei die Gesamtmenge der Filtersubstanzen z. B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 20 Gew.-%, insbesondere 1,0 bis 15,0 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische Zubereitungen zur Verfügung zu stellen, die das Haar bzw. die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen. Sie können auch als Sonnenschutzmittel fürs Haar oder die Haut dienen.The preparations according to the invention advantageously contain substances which absorb UV radiation in the UV-A and / or UV-B range, the total amount of filter substances, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic To provide preparations that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
Vorteilhafte UV-A-Filtersubstanzen im Sinne der vorliegenden Erfindung sind Dibenzoyl- methanderivate, insbesondere das 4-(tert.-Butyl)-4'-methoxydibenzoylmethan (CAS-Nr. 70356-09-1), welches von Givaudan unter der Marke Parsol® 1789 und von Merck unter der Handelsbezeichnung Eusolex® 9020 verkauft wird. Weitere vorteilhafte UV-A-Filtersubstanzen sind die Phenylen-1,4-bis-(2-benzimidazyl)-3,3'' 5,5'-tetrasulfonsäureAdvantageous UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020. Other advantageous UV-A filter substances are the phenylene-1,4-bis (2-benzimidazyl) -3,3 ''5,5'-tetrasulfonic acid
Figure imgf000007_0001
und ihre Salze, besonders die entsprechenden Natrium-, Kalium- oder Triethanolammonium- Salze, insbesondere das Phenylen-1 ,4-bis-(2-benzimidazyl)-3,3'-5,5'-tetrasulfonsäure-bis- natriumsalz
Figure imgf000007_0001
and their salts, especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis sodium salt
Figure imgf000007_0002
mit der INCI-Bezeichnung Bisimidazylate, welches beispielsweise unter der Handelsbezeichnung Neo Heliopan AP bei Haarmann & Reimer erhältlich ist.
Figure imgf000007_0002
with the INCI name bisimidazylate, which is available, for example, from Haarmann & Reimer under the trade name Neo Heliopan AP.
Femer vorteilhaft sind das 1 ,4-di(2-oxo-10-Sulfo-3-bornylidenmethyl)-Benzol und dessen Salze (besonders die entprechenden 10-Sulfato-verbindungen, insbesondere das entsprechende Natrium-, Kalium- oder Triethanolammonium-Salz), das auch als Benzol-1,4- di(2-oxo-3-bomylidenmethyl-10-sulfonsäure) bezeichnet wird und sich durch die folgende Struktur auszeichnet:Also advantageous are the 1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts (especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt) , which is also called benzene-1,4-di (2-oxo-3-bomylidenemethyl-10-sulfonic acid) and is characterized by the following structure:
Figure imgf000007_0003
Figure imgf000007_0003
Vorteilhafte UV-Filtersubstanzen im Sinne der vorliegenden Erfindung sind ferner sogenannte Breitbandfilter, d.h. Filtersubstanzen, die sowohl UV-A- als auch UV-B-Strahlung absorbieren. Vorteilhafte Breitbandfilter oder UV-B-Filtersubstanzen sind beispielsweise Bis-Resorcinyl- triazinderivate mit der folgenden Struktur:Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, ie filter substances that absorb both UV-A and UV-B radiation. Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives with the following structure:
Figure imgf000008_0001
wobei R1, R2 und R3 unabhängig voneinander gewählt werden aus der Gruppe der verzweigten und unverzweigten Alkylgruppen mit 1 bis 10 Kohlenstoffatomen bzw. ein einzelnes Wasserstoffatom darstellen. Insbesondere bevorzugt sind das 2,4-Bis-{[4-(2-Ethyl-hexyloxy)- 2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin (INCl: Aniso Triazin), weiches unter der Handelsbezeichnung Tinosorb® S bei der CIBA-Chemikalien GmbH erhältlich ist, und das 4>4,,4"-(1,3l5-Triazin-2,4,6-triyltriimino)-tris-benzoesäure-tris(2-ethylhexylester), synonym: 2>4,6-Tris-[anilino-(p-carbo-2'-ethyl-1,-hexyloxy)]-1,3,5-triazin (INCl: Octyl Triazone), welches von der BASF Aktiengesellschaft unter der Warenbezeichnung UVINUL® T 150 vertrieben wird.
Figure imgf000008_0001
where R 1 , R 2 and R 3 are independently selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom. Particularly preferred are the 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCl: Aniso triazine , soft sold under the trade name Tinosorb® S from CIBA-Chemikalien GmbH), and the 4> 4, 4 '- (1,3 l 5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2-ethylhexyl ester), synonymous: 2 > 4,6-tris [anilino- (p-carbo-2'-ethyl-1 , -hexyloxy)] - 1,3,5-triazine (INCl: octyl triazone) , which is sold by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
Auch andere UV-Filtersubstanzen, welche das StrukturmotivAlso other UV filter substances, which the structural motif
Figure imgf000008_0002
aufweisen, sind vorteilhafte UV-Filtersubstanzen im Sinne der vorliegenden Erfindung, beispielsweise die in der Europäischen Offenlegungsschrift EP 570 838 A1 beschriebenen s- Triazinderivate, deren chemische Struktur durch die generische Formel
Figure imgf000008_0002
are advantageous UV filter substances for the purposes of the present invention, for example the s-triazine derivatives described in European patent application EP 570 838 A1, the chemical structure of which is given by the generic formula
Figure imgf000009_0001
wiedergegeben wird, wobei
Figure imgf000009_0001
is reproduced, whereby
R einen verzweigten oder unverzweigten C.,-C18-Alkylrest, einen C5-C12-Cycloalkylrest, gegebenenfalls substituiert mit einer oder mehreren C C4- Alkylgruppen, darstellt,R represents a branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups,
X ein Sauerstoffatom oder eine NH-Gruppe darstellt,X represents an oxygen atom or an NH group,
Ri einen verzweigten oder unverzweigten
Figure imgf000009_0002
einen C5-C12-Cycloalkylrest, gegebenenfalls substituiert mit einer oder mehreren CrC4- Alkylgruppen, oder ein Wasserstoffatom, ein Alkalimetallatom, eine Ammoniumgruppe oder eine Gruppe der Formel
Ri a branched or unbranched
Figure imgf000009_0002
a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C r C 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
Figure imgf000009_0003
bedeutet, in welcher
Figure imgf000009_0003
means in which
A einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cycloalkyl- oder Arylrest darstellt, gegebenenfalls substituiert mit einer oder mehreren G,-C4-A represents a branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl or aryl radical, optionally substituted by one or more G, -C 4 -
Alkylgruppen, R3 ein Wasserstoffatom oder eine Methylgruppe darstellt, n eine Zahl von 1 bis 10 darstellt, R2 einen verzweigten oder unverzweigten C.,-C18-Alkylrest, einen C5-C12-Cycloalkylrest, gegebenenfalls substituiert mit einer oder mehreren C,-C4- Alkylgruppen, darstellt, wenn X die NH-Gruppe darstellt, und einen verzweigten oder unverzweigten C.,-C18-Alkylrest, einen C5-C12-Cycloalkylrest, gegebenenfalls substituiert mit einer oder mehreren CrC4- Alkylgruppen, oder ein Wasserstoffatom, ein Alkalimetallatom, eine Ammoniumgruppe oder eine Gruppe der FormelAlkyl groups, R 3 represents a hydrogen atom or a methyl group, n represents a number from 1 to 10, R 2 represents a branched or unbranched C., - C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C, -C 4 alkyl groups, when X represents the NH group, and one branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more C r C 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
Figure imgf000010_0001
bedeutet, in welcher
Figure imgf000010_0001
means in which
A einen verzweigten oder unverzweigten CrC^-Alkylrest, einen C5-C12-Cycloalkyl- oder Arylrest darstellt, gegebenenfalls substituiert mit einer oder mehreren C C4-A represents a branched or unbranched CrC ^ alkyl radical, a C 5 -C 12 cycloalkyl or aryl radical, optionally substituted by one or more CC 4 -
Alkylgruppen, R3 ein Wasserstoffatom oder eine Methylgruppe darstellt, n eine Zahl von 1 bis 10 darstellt, wenn X ein Sauerstoffatom darstellt.Alkyl groups, R 3 represents a hydrogen atom or a methyl group, n represents a number from 1 to 10 when X represents an oxygen atom.
Besonders vorteilhafte UV-Filtersubstanz im Sinne der vorliegenden Erfindung ist ferner ein unsymmetrisch substituiertes s-Triazin, dessen chemische Struktur durch die Formel A particularly advantageous UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
Figure imgf000011_0001
wiedergegeben wird, welches im Folgenden auch als Dioctylbutylamidotriazon (INCl: Dioctyl- butamidotriazone) bezeichnet wird und unter der Handelsbezeichnung UVASORB HEB bei Sigma 3V erhältlich ist.
Figure imgf000011_0001
is reproduced, which is also referred to below as dioctylbutylamidotriazon (INCl: dioctylbutamidotriazone) and is available under the trade name UVASORB HEB from Sigma 3V.
Auch in der Europäischen Offenlegungsschrift 775 698 werden vorteilhaft einzusetzende Bis- Resorcinyltriazinderivate beschrieben, deren chemische Struktur durch die generische FormelThe European patent application 775 698 also describes bis-resorcinyltriazine derivatives which are to be used advantageously and whose chemical structure is represented by the generic formula
Figure imgf000011_0002
wiedergegeben wird, wobei R1 , R2 und A-, verschiedenste organische Reste repräsentieren.
Figure imgf000011_0002
is reproduced, wherein R 1 , R 2 and A- represent a wide variety of organic radicals.
Vorteilhaft im Sinne der vorliegenden Erfindung sind ferner das 2,4-Bis-{[4-(3-suIfonato)-2- hydroxy-propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1 ,3,5-triazin Natriumsalz, das 2,4-Bis-{[4-(3-(2-Propyloxy)-2-hydroxy-propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)- 1 ,3,5-triazin, das 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-[4-(2-methoxyethyl- carboxyl)-phenylamino]-1 ,3,5-triazin, das 2,4-Bis-{[4-(3-(2-propyloxy)-2-hydroxy-propyloxy)- 2-hydroxy]-phenyl}-6-[4-(2-ethyl-carboxyl)-phenylamino]-1 ,3,5-triazin, das 2,4-Bis-{[4-(2- ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(1-methyI-pyrrol-2-yl)-1 ,3,5-triazin, das 2,4-Bis-{[4- tris(trimethylsiloxy-silylpropyIoxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1 ,3,5-triazin, das 2,4-Bis-{[4-(2"-methylpropenyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin und das 2,4-Bis-{[4-(1',1',1',3',5',5',5'-Heptamethylsiloxy-2"-methyl-propyloxy)-2-hydroxy]-phenyl- 6-(4-methoxyphenyl)-1,3,5-triazin.Also advantageous for the purposes of the present invention are the 2,4-bis - {[4- (3-suIfonato) -2-hydroxypropyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1, 3,5-triazine sodium salt, the 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) - 1,3,5-triazine, the 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- [4- (2-methoxyethylcarboxyl) phenylamino] -1, 3,5-triazine, the 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxypropyloxy) - 2-hydroxy] phenyl} -6- [4- (2-ethylcarboxyl) phenylamino] -1, 3,5-triazine, the 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- (1-methyl-pyrrol-2-yl) -1, 3,5-triazine, the 2,4-bis - {[4-tris (trimethylsiloxysilylpropyloxy) -2 -hydroxy] phenyl} -6- (4-methoxyphenyl) -1, 3,5-triazine, the 2,4-bis - {[4- (2 "-methylpropenyloxy) -2-hydroxy] phenyl} -6 - (4-methoxyphenyl) -1,3,5-triazine and the 2,4-bis - {[4- (1 ', 1', 1 ', 3', 5 ', 5', 5'-heptamethylsiloxy- 2 "-methyl-propyloxy) -2-hydroxy] phenyl- 6- (4-methoxyphenyl) -1,3,5-triazine.
Ein vorteilhafter Breitbandfilter im Sinne der vorliegenden Erfindung ist das 2,2'-Methylen-bis- (6-(2H-benzotriazol-2-yl)-4-(1 , 1 ,3,3-tetramethylbutyl)-phenol) [INCl: Bisoctyltriazol], welches durch die chemische StrukturformelAn advantageous broadband filter for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) [INCl : Bisoctyltriazole], which is characterized by the chemical structural formula
Figure imgf000012_0001
gekennzeichnet ist und unter der Handelsbezeichnung Tinosorb® M bei der CIBA- Chemikalien GmbH erhältlich ist.
Figure imgf000012_0001
is marked and is available under the trade name Tinosorb® M from CIBA Chemical GmbH.
Vorteilhafter Breitbandfilter im Sinne der vorliegenden Erfindung ist ferner das 2-(2H- benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1 ,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxa- nyl]propyl]-phenol (CAS-Nr.: 155633-54-8) mit der INCI-Bezeichnung Drometrizole Trisiloxa- ne, welches durch die chemische StrukturformelAnother advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1, 3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula
Figure imgf000012_0002
gekennzeichnet ist. Die UV-B-Filter können öllöslich oder wasserlöslich sein. Vorteilhafte öiiösliche UV-B- Filtersubstanzen sind z. B.:
Figure imgf000012_0002
is marked. The UV-B filters can be oil-soluble or water-soluble. Advantageous oil-soluble UV-B filter substances are e.g. B .:
■ 3-Benzylidencampher-Derivate, vorzugsweise 3-(4-Methylbenzyliden)campher, 3-Benzy- lidencampher;■ 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
■ 4-Aminobenzoesäure-Derivate, vorzugsweise 4-(Dimethylamino)-benzoesäure(2-ethylhe- xyl)ester, 4-(Dimethylamino)benzoesäureamylester;■ 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
• 2,4,6-Trianilino-(p-carbo-2'-ethyl-1 '-hexyloxy)-1 ,3,5-triazin;2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine;
■ Ester der Benzalmalonsäure, vorzugsweise 4-Methoxybenzalmalonsäuredi(2-ethylhexyl)- ester;■ esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
■ Ester der Zimtsäure, vorzugsweise 4-Methoxyzimtsäure(2-ethylhexyl)ester, 4-Methoxy- zimtsäureisopentylester;■ esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
Derivate des Benzophenons, vorzugsweise 2-Hydroxy-4-methoxybenzophenon, 2- Hydroxy-4-methoxy-4'-methylbenzophenon, 2,2'-Dihydroxy-4-methoxybenzophenon Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
sowie an Polymere gebundene UV-Filter. as well as UV filters bound to polymers.
Vorteilhafte wasserlösliche UV-B-Filtersubstanzen sind z. B.:Advantageous water-soluble UV-B filter substances are e.g. B .:
Salze der 2-Phenylbenzimidazol-5-sulfonsäure, wie ihr Natrium-, Kalium- oder ihr Triethanolammonium-Salz, sowie die Sulfonsäure selbst; salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself;
Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z. B. 4-(2-Oxo-3-bomylidenme- thyl)benzolsulfonsäure, 2-Methyl-5-(2-oxo-3-bornylidenmethyl)sulfonsäure und deren Salze. sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-oxo-3-bomylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene methyl) sulfonic acid and salts thereof.
Eine weiterere erfindungsgemäß vorteilhaft zu verwendende Lichtschutzfiltersubstanz ist das Ethylhexyi-2-cyano-3,3-diphenylacrylat (Octocrylen), welches von BASF unter der Bezeichnung Uvinul® N 539 erhältlich ist und sich durch folgende Struktur auszeichnet:A further light protection filter substance to be used advantageously according to the invention is ethylhexyi-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul ® N 539 and is distinguished by the following structure:
Figure imgf000013_0001
Es kann auch von erheblichem Vorteil sein, polymergebundene oder polymere UV-Filtersubstanzen in Zubereitungen gemäß der vorliegenden Erfindung zu verwenden, insbesondere solche, wie sie in der WO-A-92/20690 beschrieben werden.
Figure imgf000013_0001
It can also be of considerable advantage to use polymer-bound or polymeric UV filter substances in preparations according to the present invention, in particular those as described in WO-A-92/20690.
Ferner kann es gegebenenfalls von Vorteil sein, erfindungsgemäß weitere UV-A- und/oder UV-B-Filter in kosmetische oder dermatologische Zubereitungen einzuarbeiten, beispielsweise bestimmte Salicylsäurederivate wie 4-lsopropylbenzylsalicylat, 2-Ethylhexylsalicylat (= Octylsalicylat), Homomenthylsalicylat.It may also be advantageous, if appropriate, to incorporate further UV-A and / or UV-B filters into cosmetic or dermatological preparations, for example certain salicylic acid derivatives such as 4-isopropylbenzyl salicylate, 2-ethylhexyl salicylate (= octyl salicylate), homomenthyl salicylate.
Die Liste der genannten UV-Filter, die im Sinne der vorliegenden Erfindung eingesetzt werden können, soll selbstverständlich nicht limitierend sein.The list of the UV filters mentioned, which can be used in the sense of the present invention, should of course not be limiting.
Es ist erfindungsgemäß vorteilhaft, das molare Verhältnis der unter (a) und (b) genannten Substanzen aus dem Bereich von 10 : 1 bis 1 : 10 , bevorzugt 5 : 1 bis 1 : 5, insbesondere bevorzugt 2 : 1 bis 1 : 2 zu wählen.It is advantageous according to the invention to add the molar ratio of the substances mentioned under (a) and (b) in the range from 10: 1 to 1:10, preferably 5: 1 to 1: 5, particularly preferably 2: 1 to 1: 2 choose.
Es ist erfindungsgemäß insbesondere äußerst vorteilhaft, kosmetische oder topische dermatologische Zubereitungen mit einem wirksamen Gehalt an Wogonin zur kosmetischen oder dermatologischen Behandlung oder Prophylaxe unerwünschter Hautzustände zu verwenden.It is particularly advantageous according to the invention to use cosmetic or topical dermatological preparations with an effective wogonin content for cosmetic or dermatological treatment or prophylaxis of undesirable skin conditions.
Erfindungsgemäß können Zubereitungen, welche die erfindungsgemäßen Wirkstoffkombinationen enthalten, übliche Antioxidantien eingesetzt werden.According to the invention, preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
Vorteilhaft werden die Antioxidantien gewählt aus der Gruppe bestehend aus Aminosäuren (z.B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate, Imidazole (z.B. Urocaninsäu- re) und deren Derivate, Peptide wie D,L-Carnosin, D-Camosin, L-Carnosin und deren Derivate (z.B. Anserin), Carotinoide, Carotine (z.B. -Carotin, ß-Carotin, Lycopin) und deren Derivate, Aurothioglucose, Propylthiouracil und andere Thiole (z.B. Thioredoxin, Glutathion, Cy- stein, Cystin, Cystamin und deren Glycosyl-, N-Acetyl-, Methyl-, Ethyl-, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, γ-Linoleyl-, Cholesteryl- und Glycerylester) sowie deren Salze, Dilaurylthiodipropionat, Distearylthiodipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide, Lipide, Nukleotide, Nukleoside und Salze) sowie Sulf- oximinverbindungen (z.B. Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-, Heptathioninsulfoximin) in sehr geringen verträglichen Dosierungen (z.B. pmol bis μmol/kg), ferner (Metall)-Chelatoren (z.B. α-Hydroxyfettsäuren, Palmitinsäure, Phytin- säure, Lactoferrin), α-Hydroxysäuren (z.B. Citronensäure, Milchsäure, Apfelsäure), Humin- säure, Gallensäure, Gallenextrakte, Bilirubin, Biliverdin, EDTA, EGTA und deren Derivate, ungesättigte Fettsäuren und deren Derivate (z.B. γ-Linolensäure, Linolsäure, Ölsäure), Fol- säure und deren Derivate, Alanindiessigsäure, Flavonoide, Polyphenole, Catechine, Vitamin C und Derivate (z.B. Ascorbylpalmitat, Mg-Ascorbylphosphat, Ascorbylacetat), Tocopherole und Derivate (z.B. Vitamin-E-acetat), sowie Koniferylbenzoat des Benzoeharzes, Rutinsäure und deren Derivate, Ferulasäure und deren Derivate, Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguajakharzsäure, Nordihydroguajaretsäure, Trihydroxybutyrophenon, Harnsäure und deren Derivate, Mannose und deren Derivate, Zink und dessen Derivate (z.B. ZnO, ZnSO4) Selen und dessen Derivate (z.B. Selenmethionin), Stilbene und deren Derivate (z.B. Stilbenoxid, Trans-Stilbenoxid) und die erfindungsgemäß geeigneten Derivate (Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) dieser genannten Wirkstoffe.The antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-camosine, L- Carnosine and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. carotene, ß-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cystine, cystine, cystamine and their glycosyl- , N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (eg buthioninsulfoximines, homocysteine sulfoximine, buthioninsulfones, Penta-, hexa-, heptathioninsulfoximine) in very low tolerable doses (e.g. pmol to μmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, Lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (eg γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, alanine diacetic acid, flavonoids , Polyphenols, catechins, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), and coniferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylated hydroxytoluene , Nordihydroguajakharzäure, Nordihydroguajaretsäure, trihydroxybutyrophenon, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO 4 ) selenium and its derivatives (eg selenium methionine), stilbenes and their derivatives (eg stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances.
Die Menge der Antioxidantien (eine oder mehrere Verbindungen) in den Zubereitungen beträgt vorzugsweise 0,001 bis 30 Gew.-%, besonders bevorzugt 0,05 - 20 Gew.-%, insbesondere 1 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung.The amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
Die Prophylaxe bzw. die kosmetische oder dermatologische Behandlung mit den kosmetischen oder topischen dermatologischen Zubereitungen mit einem wirksamen Gehalt an Wogonin erfolgt in der üblichen Weise, und zwar dergestalt, daß die kosmetischen oder topischen dermatologischen Zubereitungen mit einem wirksamen Gehalt an Wogonin auf die betroffenen Hautstellen aufgetragen wird.The prophylaxis or the cosmetic or dermatological treatment with the cosmetic or topical dermatological preparations with an effective content of wogonin is carried out in the usual way, namely in such a way that the cosmetic or topical dermatological preparations with an effective content of wogonin are applied to the affected skin areas becomes.
Vorteilhaft kann Wogonin eingearbeitet werden in übliche kosmetische und dermatologische Zubereitungen, welche in verschiedenen Formen vorliegen können. So können sie z.B. eine Lösung, eine Emulsion vom Typ Wasser-in-ÖI (W/O) oder vom Typ Öl-in-Wasser (O/W), o- der eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-ÖI-in-Wasser (W/OΛ/V) o- der Öl-in-Wasser-in-ÖI (O/W/O), eine Hydrodispersion oder Lipodispersion, ein Gel, einen festen Stift oder auch ein Aerosol darstellen.Wogonin can advantageously be incorporated into conventional cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / OΛ / V) o- the oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.
Erfindungsgemäße Emulsionen im Sinne der vorliegenden Erfindung, z.B. in Form einer Creme, einer Lotion, einer kosmetischen Milch sind vorteilhaft und enthalten z.B. Fette, Öle, Wachse und/oder andere Fettkörper, sowie Wasser und einen oder mehrere Emulgatoren, wie sie üblicherweise für einen solchen Typ der Formulierung verwendet werden.Emulsions according to the invention in the sense of the present invention, for example in the form of a Cream, a lotion, a cosmetic milk are advantageous and contain, for example, fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
Es ist auch möglich und vorteilhaft im Sinne der vorliegenden Erfindung, Wogonin in wäßrige Systeme bzw. Tensidzubereitungen zur Reinigung der Haut und der Haare einzufügen.It is also possible and advantageous for the purposes of the present invention to add wogonin to aqueous systems or surfactant preparations for cleaning the skin and hair.
Es ist dem Fachmanne natürlich bekannt, daß anspruchsvolle kosmetische Zusammensetzungen zumeist nicht ohne die üblichen Hilfs- und Zusatzstoffe denkbar sind. Die erfindungsgemäßen kosmetischen Zubereitungen können daher kosmetische Hilfsstoffe enthalten, wie sie üblicherweise in solchen Zubereitungen verwendet werden, z.B. Konservierungsmittel, Bakterizide, desodorierend wirkende Substanzen, Antitranspirantien, Insektenrepellentien, Vitamine, Mittel zum Verhindern des Schäumens, Farbstoffe, Pigmente mit färbender Wirkung, Verdickungsmittel, weichmachende Substanzen, anfeuchtende und/oder feuchthaltende Substanzen, Fette, Öle, Wachse oder andere übliche Bestandteile einer kosmetischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösungsmittel oder Silikonderivate.It is of course known to the person skilled in the art that sophisticated cosmetic compositions are usually inconceivable without the customary auxiliaries and additives. The cosmetic preparations according to the invention can therefore contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic Formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Mutatis mutandis gelten entsprechende Anforderungen an die Formulierung medizinischer Zubereitungen.Mutatis mutandis, corresponding requirements apply to the formulation of medical preparations.
Medizinische topische Zusammensetzungen im Sinne der vorliegenden Erfindung enthalten in der Regel ein oder mehrere Medikamente in wirksamer Konzentration.- Der Einfachheit halber wird zur sauberen Unterscheidung zwischen kosmetischer und medizinischer Anwendung und entsprechenden Produkten auf die gesetzlichen Bestimmungen der Bundesrepublik Deutschland verwiesen (z.B. Kosmetikverordnung, Lebensmittel- und Arzneimittelgesetz).Medical topical compositions in the sense of the present invention generally contain one or more drugs in effective concentration. For the sake of simplicity, for a clear distinction between cosmetic and medical use and corresponding products, reference is made to the legal provisions of the Federal Republic of Germany (e.g. cosmetics regulation, food and drug law).
Erfindungsgemäße kosmetische und dermatologische Zubereitungen enthalten vorteilhaft außerdem anorganische Pigmente auf Basis von Metalloxiden und/oder anderen in Wasser schwerlöslichen oder unlöslichen Metallverbindungen, insbesondere der Oxide des Titans (TiO2), Zinks (ZnO), Eisens (z.B. Fe2O3), Zirkoniums (ZrO2), Siliciums (SiO2), Mangans (z.B. MnO), Aluminiums (AI2O3), Cers (z.B. Ce2O3), Mischoxiden der entsprechenden Metalle so- wie Abmischungen aus solchen Oxiden. Besonders bevorzugt handelt es sich um Pigmente auf der Basis von TiO2.Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 O 3 ), cerium (e.g. Ce 2 O 3 ), mixed oxides of the corresponding metals, like mixtures of such oxides. Pigments based on TiO 2 are particularly preferred.
Es ist besonders vorteilhaft im Sinne der vorliegenden Erfindung, wenngleich nicht zwingend, wenn die anorganischen Pigmente in hydrophober Form vorliegen, d.h., daß sie oberflächlich wasserabweisend behandelt sind. Diese Oberflächenbehandlung kann darin bestehen, daß die Pigmente nach an sich bekannten Verfahren mit einer dünnen hydrophoben Schicht versehen werden.It is particularly advantageous within the meaning of the present invention, although not mandatory, if the inorganic pigments are in hydrophobic form, i.e. that they have been treated to be water-repellent on the surface. This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
Eines solcher Verfahren besteht beispielsweise darin, daß die hydrophobe Oberflächenschicht nach einer Reaktion gemäßOne such method is, for example, that the hydrophobic surface layer after a reaction
n TiO2+ m (RO)3Si-R' -> n TiO2 (oberfl.)n TiO 2 + m (RO) 3 Si-R '-> n TiO 2 (surface)
erzeugt wird, n und m sind dabei nach Belieben einzusetzende stöchiometrische Parameter, R und R' die gewünschten organischen Reste. Beispielsweise in Analogie zu DE-OS 33 14 742 dargestellte hydrophobisierte Pigmente sind von Vorteil.is generated, n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals. For example, hydrophobized pigments shown in analogy to DE-OS 33 14 742 are advantageous.
Vorteilhafte TiO2-Pigmente sind beispielsweise unter den Handelsbezeichnungen MT 100 T von der Firma TAYCA, ferner M 160 von der Firma Kemira sowie T 805 von der Firma Degussa erhältlich.Advantageous TiO 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
Erfindungsgemäße Zubereitungen können, zumal wenn kristalline oder mikrokristalline Festkörper, beispielsweise anorganische Mikropigmente in die erfindungsgemäßen Zubereitungen eingearbeitet werden sollen, auch anionische, nichtionische und/oder amphotere Ten- side enthalten. Tenside sind amphiphile Stoffe, die organische, unpolare Substanzen in Wasser lösen können.Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention. Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
Bei den hydrophilen Anteilen eines Tensidmoleküls handelt es sich meist um polare funk- tionelle Gruppen, beispielweise -COO", -OSO3 2', -SO3 ", während die hydrophoben Teile in der Regel unpolare Kohlenwasserstoffreste darstellen. Tenside werden im allgemeinen nach Art und Ladung des hydrophilen Molekülteils klassifiziert. Hierbei können vier Gruppen unterschieden werden: • anionische Tenside,The hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OSO 3 2 ' , -SO 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon radicals. Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups: Anionic surfactants,
• kationische Tenside,Cationic surfactants,
• amphotere Tenside und• amphoteric surfactants and
• nichtionische Tenside.• nonionic surfactants.
Anionische Tenside weisen als funktionelle Gruppen in der Regel Carboxylat-, Sulfat- oder Sulfonatgruppen auf. In wäßriger Lösung bilden sie im sauren oder neutralen Milieu negativ geladene organische Ionen. Kationische Tenside sind beinahe ausschließlich durch das Vorhandensein einer quaternären Ammoniumgruppe gekennzeichnet. In wäßriger Lösung bilden sie im sauren oder neutralen Milieu positiv geladene organische Ionen. Amphotere Tenside enthalten sowohl anionische als auch kationische Gruppen und verhalten sich demnach in wäßriger Lösung je nach pH-Wert wie anionische oder kationische Tenside. Im stark sauren Milieu besitzen sie eine positive und im alkalischen Milieu eine negative Ladung. Im neutralen pH-Bereich hingegen sind sie zwitterionisch, wie das folgende Beispiel verdeutlichen soll:Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
RNH2 +CH2CH2COOH X" (bei pH=2) X" = beliebiges Anion, z.B. Cl" RNH 2 + CH 2 CH 2 COOH X " (at pH = 2) X " = any anion, eg Cl "
RNH2 +CH2CH2COO- (bei pH=7)RNH 2 + CH 2 CH 2 COO- (at pH = 7)
RNHCH2CH2COO- B+ (bei H=12) B+ = beliebiges Kation, z.B. Na+ RNHCH 2 CH 2 COO- B + (at H = 12) B + = any cation, e.g. Na +
Typisch für nicht-ionische Tenside sind Polyether-Ketten. Nicht-ionische Tenside bilden in wäßrigem Medium keine Ionen.Polyether chains are typical of non-ionic surfactants. Non-ionic surfactants do not form ions in an aqueous medium.
A. Anionische TensideA. Anionic surfactants
Vorteilhaft zu verwendende anionische Tenside sindAnionic surfactants to be used advantageously
Acylaminosäuren (und deren Salze), wieAcylamino acids (and their salts), such as
1. Acylglutamate, beispielsweise Natriumacylglutamat, Di-TEA-palmitoylaspartat und Natrium Caprylic/ Capric Glutamat,1. acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
2. Acylpeptide, beispielsweise Palmitoyl-hydrolysiertes Milchprotein, Natrium Cocoyl- hydrolysiertes Soja Protein und Natrium-/ Kalium Cocoyl-hydrolysiertes Kollagen,2. acyl peptides, for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
3. Sarcosinate, beispielsweise Myristoyl Sarcosin, TEA-Iauroyl Sarcosinat, Natrium- lauroylsarcosinat und Natriumcocoylsarkosinat,3. sarcosinates, for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
4. Taurate, beispielsweise Natriumlauroyltaurat und Natriummethylcocoyftaurat, 5. AcylLactylate, lauroyllactylat, Caproyllactylat4. taurates, for example sodium lauroyl taurate and sodium methyl cocoyftaurate, 5. Acyl lactylates, lauroyl lactylate, caproyl lactylate
6. Alaninate Carbonsäuren und Derivate, wie6. Alaninate carboxylic acids and derivatives such as
1. Carbonsäuren, beispielsweise Laurinsäure, Aluminiumstearat, Magnesiumalkanolat und Zinkundecylenat,1. carboxylic acids, for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
2. Ester-Carbonsäuren, beispielsweise Calciumstearoyllactylat, Laureth-6 Citrat und Natrium PEG-4 Lauramidcarboxylat,2. ester carboxylic acids, for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
3. Ether-Carbonsäuren, beispielsweise Natriumlaureth-13 Carboxylat und, Natrium PEG-6 Cocamide Carboxylat,3. ether carboxylic acids, for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,
Phosphorsäureester und Salze, wie beispielsweise DEA-Oleth-10-Phosphat und Dilaureth-4 Phosphat,Phosphoric acid esters and salts, such as DEA-oleth-10-phosphate and dilaureth-4-phosphate,
Sulfonsäuren und Salze, wieSulfonic acids and salts such as
1. Acyl-isethionate, z.B. Natrium-/ Ammoniumcocoyl-isethionat,1. acyl isethionates, e.g. Sodium / ammonium cocoyl isethionate,
2. Alkylarylsulfonate,2. alkylarylsulfonates,
3. Alkylsulfonate, beispielsweise Natriumcocosmonoglyceridsulfat, Natrium Cι2-14 Olefin- sulfonat, Natriumlaurylsulfoacetat und Magnesium PEG-3 Cocamidsulfat,3. alkyl sulfonates, for example sodium coconut monoglyceride sulfate, sodium Cι 2-14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
4. Sulfosuccinate, beispielsweise Dioctylnatriumsulfosuccinat, Dinatriumlaurethsulfosuc- cinat, Dinatriumlaurylsulfosuccinat und Dinatriumundecylenamido MEA-Sulfosuccinat4. Sulfosuccinates, for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
sowie Schwefelsäureester, wieas well as sulfuric acid esters, such as
1. Alkylethersulfat, beispielsweise Natrium-, Ammonium-, Magnesium-, MlPA-, TIPA- Lau- rethsulfat, Natrium myrethsulfat und Natrium C12-13 Parethsulfat,1. alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C 12-13 pareth sulfate,
2. Alkylsulfate, beispielsweise Natrium-, Ammonium- und TEA- Lauryisulfat.2. Alkyl sulfates, for example sodium, ammonium and TEA lauryl sulfate.
B. Kationische TensideB. Cationic surfactants
Vorteilhaft zu verwendende kationische Tenside sindCationic surfactants to be used advantageously
1. Alkylamine,1. alkylamines,
2. Alkylimidazole,2. alkylimidazoles,
3. Ethoxylierte Amine und3. Ethoxylated amines and
4. Quaternäre Tenside. 5. Esterquats4. Quaternary surfactants. 5. Esterquats
Quaternäre Tenside enthalten mindestens ein N-Atom, das mit 4 Alkyl- oder Arylgruppen kovalent verbunden ist. Dies führt, unabhängig vom pH Wert, zu einer positiven Ladung. Vorteilhaft sind, Alkylbetain, Alkylamidopropylbetain und Alkyl-amidopropylhydroxysulfain. Die erfindungsgemäß verwendeten kationischen Tenside können ferner bevorzugt gewählt werden aus der Gruppe der quatemären Ammoniumverbindungen, insbesondere Ben- zyltrialkylammoniumchloride oder -bromide, wie beispielsweise Benzyldimethylstea- rylammoniumchlorid, ferner Alkyltrialkylammoniumsalze, beispielsweise beispielsweise Cetyl- trimethylammoniumchlorid oder -bromid, Alkyldimethylhydroxyethylammoniumchloride oder - bromide, Dialkyldimethylammoniumchloride oder -bromide, Alkylamidethyltrimethylammoni- umethersulfate, Alkylpyridiniumsalze, beispielsweise Lauryl- oder Cetylpyrimidiniumchlorid, Imidazolinderivate und Verbindungen mit kationischem Charakter wie Aminoxide, beispielsweise Alkyldimethylaminoxide oder Alkylaminoethyldimethylaminoxide. Vorteilhaft sind insbesondere Cetyltrimethylammoniumsalze zu verwenden.Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge. Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous. The cationic surfactants used in the invention can be also preferably selected from the group of quaternary ammonium compounds, in particular benzene zyltrialkylammoniumchloride or bromides, such as Benzyldimethylstea- rylammoniumchlorid, also alkyltrialkylammonium, such as for example, cetyl trimethyl ammonium chloride or bromide, alkyldimethylhydroxyethylammonium chlorides or - bromides, dialkyldimethylammonium chlorides or bromides, alkylamidethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammonium salts are particularly advantageous.
C. Amphotere TensideC. Amphoteric surfactants
Vorteilhaft zu verwendende amphotere Tenside sindAmphoteric surfactants to be used advantageously
1. Acyl-/dialkylethylendiamin, beispielsweise Natriumacylamphoacetat, Dinatriumacyl- amphodipropionat, Dinatriumalkylamphodiacetat, Natriumacylamphohydroxypropylsul- fonat, Dinatriumacylamphodiacetat und Natriumacylamphopropionat,1. acyl / dialkyl ethylenediamine, for example sodium acyl amphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxypropyl sulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
2. N-Alkylaminosäuren, beispielsweise Aminopropylalkylglutamid, Alkylaminopropion- säure, Natriumalkylimidodipropionat und Lauroamphocarboxyglycinat.2. N-alkylamino acids, for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
D. Nicht-ionische TensideD. Non-ionic surfactants
Vorteilhaft zu verwendende nicht-ionische Tenside sindNon-ionic surfactants to be used advantageously
1. Alkohole,1. alcohols,
2. Alkanolamide, wie Cocamide MEA/ DEA/ MIPA,2. alkanolamides, such as cocamides MEA / DEA / MIPA,
3. Aminoxide, wie Cocoamidopropylaminoxid,3. amine oxides, such as cocoamidopropylamine oxide,
4. Ester, die durch Veresterung von Carbonsäuren mit Ethylenoxid, Glycerin, Sorbitan oder anderen Alkoholen entstehen,4. esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
5. Ether, beispielsweise ethoxylierte/propoxylierte Alkohole, ethoxylierte/ propoxylierte Ester, ethoxylierte/ propoxylierte Glycerinester, ethoxylierte/ propoxylierte Cholesterine, ethoxylierte/ propoxylierte Triglyceridester, ethoxyliertes propoxyliert.es Lanolin, ethoxy- lierte/ propoxylierte Polysiloxane, propoxylierte POE-Ether und Alkylpolyglycoside wie5. ethers, for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterols, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated es lanolin, ethoxy lated / propoxylated polysiloxanes, propoxylated POE ethers and alkyl polyglycosides such as
Laurylglucosid, Decylglycosid und Cocoglycosid. 6. Sucroseester, -EtherLauryl glucoside, decyl glycoside and cocoglycoside. 6. sucrose esters, ether
7 Polyglycerinester, Diglycerinester, Monoglycerinester 8. Methylglucosester, Ester von Hydroxysäuren7 polyglycerol esters, diglycerol esters, monoglycerol esters 8. methyl glucose esters, esters of hydroxy acids
Vorteilhaft ist ferner die Verwendung einer Kombination von anionischen und/oder ampho- teren Tensiden mit einem oder mehreren nicht-ionischen Tensiden.It is also advantageous to use a combination of anionic and / or amphoteric surfactants with one or more nonionic surfactants.
Die oberflächenaktive Substanz kann in einer Konzentration zwischen 1 und 95 Gew.-% in den erfindungsgemäßen Zubereitungen vorliegen, bezogen auf das Gesamtgewicht der Zubereitungen.The surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 95% by weight, based on the total weight of the preparations.
Die Lipidphase der erfindungsgemäßen kosmetischen oder dermatologischen Emulsionen kann vorteilhaft gewählt werden aus folgender Substanzgruppe: Mineralöle, MineralwachseThe lipid phase of the cosmetic or dermatological emulsions according to the invention can advantageously be selected from the following group of substances: mineral oils, mineral waxes
Öle, wie Triglyceride der Caprin- oder der Caprylsäure, ferner natürliche Öle wie z.B. Rizinusöl;Oils such as triglycerides of capric or caprylic acid as well as natural oils such as e.g. Castor oil;
Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z.B. mit Isopropanol, Propylengly- kol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren; Alkylbenzoate;Fats, waxes and other natural and synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids; benzoates;
Silikonöle wie Dimethylpolysiloxane, Diethylpolysiloxane, Diphenylpolysiloxane sowie Mischformen daraus.Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
Die Ölphase der Emulsionen der vorliegenden Erfindung wird vorteilhaft gewählt aus der Gruppe der Ester aus gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkancarbonsäuren einer Kettenlänge von 3 bis 30 C-Atomen und gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkoholen einer Kettenlänge von 3 bis 30 C-Atomen, aus der Gruppe der Ester aus aromatischen Carbonsäuren und gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkoholen einer Kettenlänge von 3 bis 30 C-Atomen. Solche Esteröle können dann vorteilhaft gewählt werden aus der Gruppe Isopropylmyristat, Isopropylpalmitat, Isopropylstearat, Isopropyloleat, n-Butylstearat, n-Hexyllaurat, n-Decyloleat, Isooctylstearat, Isononylstearat, Isononylisononanoat, 2- Ethylhexylpalmitat, 2-Ethylhexyllaurat, 2-Hexyldecylstearat, 2-Octyldodecylpalmitat, Oleyl- oleat, Oleylerucat, Erucyloleat, Erucylerucat sowie synthetische, halbsynthetische und natürliche Gemische solcher Ester, z.B. Jojobaöl.The oil phase of the emulsions of the present invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms. Such ester oils can then advantageously be chosen from the Group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethyl hexyl lauryl, 2-ethyl hexyl lauryl, octyl ethyl acetate, 2-ethyl hexyl laurate, , Erucylerucate and synthetic, semisynthetic and natural mixtures of such esters, for example jojoba oil.
Ferner kann die Ölphase vorteilhaft gewählt werden aus der Gruppe der verzweigten und unverzweigten Kohlenwasserstoffe und -wachse, der Silkonöle, der Dialkylether, der Gruppe der gesättigten oder ungesättigten, verzweigten oder unverzweigten Alkohole, sowie der Fettsäuretriglyceride, namentlich der Triglycerinester gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkancarbonsäuren einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C-Atomen. Die Fettsäuretriglyceride können beispielsweise vorteilhaft gewählt werden aus der Gruppe der synthetischen, halbsynthetischen und natürlichen Öle, z.B. Olivenöl, Sonnenblumenöl, Sojaöl, Erdnußöl, Rapsöl, Mandelöl, Palmöl, Kokosöl, Palmkemöl und dergleichen mehr.Furthermore, the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms. The fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
Auch beliebige Abmischungen solcher Öl- und Wachskomponenten sind vorteilhaft im Sinne der vorliegenden Erfindung einzusetzen. Es kann auch gegebenenfalls vorteilhaft sein, Wachse, beispielsweise Cetylpalmitat, als alleinige Lipidkomponente der Ölphase einzusetzen.Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
Vorteilhaft wird die Ölphase gewählt aus der Gruppe 2-Ethylhexylisostearat, Octyldodecanol, Isotridecylisononanoat, Isoeicosan, 2-Ethylhexylcocoat, C12-15-Alkylbenzoat, Capryl-Caprin- säure-triglycerid, Dicaprylylether.The oil phase is advantageously selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
Besonders vorteilhaft sind Mischungen aus C12-15-Alkylbenzoat und 2-Ethylhexylisostearat, Mischungen aus C12-15-Alkylbenzoat und Isotridecylisononanoat sowie Mischungen aus C12-15- Alkylbenzoat, 2-Ethylhexylisostearat und Isotridecylisononanoat.Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12-15 -alkyl benzoate and isotridecyl isononanoate and mixtures of C 12-15 - benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
Von den Kohlenwasserstoffen sind Paraffinöl, Squalan und Squalen vorteilhaft im Sinne der vorliegenden Erfindung zu verwenden. Vorteilhaft kann die Ölphase ferner einen Gehalt an cyclischen oder linearen Silikonölen aufweisen oder vollständig aus solchen Ölen bestehen, wobei allerdings bevorzugt wird, außer dem Silikonöl oder den Silikonölen einen zusätzlichen Gehalt an anderen Ölphasenkom- ponenten zu verwenden. Solche Silicone oder Siliconöle können als Monomere vorliegen, welche in der Regel durch Strukturelemente charakterisiert sind, wie folgt:Of the hydrocarbons, paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention. The oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils. Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
Figure imgf000023_0001
Figure imgf000023_0001
Als erfindungsgemäß vorteilhaft einzusetzenden linearen Silicone mit mehreren Siloxyl- einheiten werden im allgemeinen durch Strukturelemente charakterisiert wie folgt:Linear silicones with a plurality of siloxyl units which can advantageously be used according to the invention are generally characterized by structural elements as follows:
Figure imgf000023_0002
wobei die Siliciumatome mit gleichen oder unterschiedlichen Alkylresten und/oder Arylresten substituiert werden können, welche hier verallgemeinernd durch die Reste R., - R4dargestellt sind (will sagen, daß die Anzahl der unterschiedlichen Reste nicht notwendig auf bis zu 4 beschränkt ist), m kann dabei Werte von 2 - 200.000 annehmen.
Figure imgf000023_0002
wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R., - R 4 (to say that the number of different radicals is not necessarily limited to up to 4), m can assume values from 2 - 200,000.
Erfindungsgemäß vorteilhaft einzusetzende cyclische Silicone werden im allgemeinen durch Strukturelemente charakterisiert, wie folgtCyclic silicones to be used advantageously according to the invention are generally characterized by structural elements as follows
Figure imgf000023_0003
wobei die Siliciumatome mit gleichen oder unterschiedlichen Alkylresten und/oder Arylresten substituiert werden können, welche hier verallgemeinernd durch die Reste R1 - R4 dargestellt sind (will sagen, daß die Anzahl der unterschiedlichen Reste nicht notwendig auf bis zu 4 beschränkt ist), n kann dabei Werte von 3/2 bis 20 annehmen. Gebrochene Werte für n be- rücksichtigen, daß ungeradzahlige Anzahlen von Siloxylgruppen im Cyclus vorhanden sein können.
Figure imgf000023_0003
wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R 1 - R 4 (to say that the number of different radicals is not necessarily limited to up to 4), n can take values from 3/2 to 20. Fractional values for n take into account that odd numbers of siloxyl groups may be present in the cycle.
Vorteilhaft wird Cyclomethicon (z.B. Decamethylcyclopentasiloxan) als erfindungsgemäß zu verwendendes Silikonöl eingesetzt. Aber auch andere Silikonöle sind vorteilhaft im Sinne der vorliegenden Erfindung zu verwenden, beispielsweise Undecamethylcyclotrisiloxan, Polydi- methylsiloxan, Poly(methylphenylsiloxan), Cetyldimethicon, Behenoxydimethicon.Cyclomethicone (e.g. decamethylcyclopentasiloxane) is advantageously used as the silicone oil to be used according to the invention. However, other silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
Vorteilhaft sind ferner Mischungen aus Cyclomethicon und Isotridecylisononanoat, sowie solche aus Cyclomethicon und 2-Ethylhexylisostearat.Mixtures of cyclomethicone and isotridecyl isononanoate and those of cyclomethicone and 2-ethylhexyl isostearate are also advantageous.
Es ist aber auch vorteilhaft, Silikonöle ähnlicher Konstitution wie der vorstehend bezeichneten Verbindungen zu wählen, deren organische Seitenketten derivatisiert, beispielsweise polyethoxyliert und/oder polypropoxyliert sind. Dazu zählen beispielsweise Polysiloxan- polyalkyl-polyether-copolymere wie das Cetyl-Dimethicon-Copolyol, das (Cetyl-Dimethicon- Copolyol (und) PolyglyceryI-4-lsostearat (und) Hexyliaurat)However, it is also advantageous to choose silicone oils of a similar constitution to the compounds described above, the organic side chains of which are derivatized, for example polyethoxylated and / or polypropoxylated. These include, for example, polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl-dimethicone copolyol (and) polyglycery I-4-isostearate (and) hexyliaurate)
Besonders vorteilhaft sind ferner Mischungen aus Cyclomethicon und Isotridecylisononanoat, aus Cyclomethicon und 2-Ethylhexylisostearat.Mixtures of cyclomethicone and isotridecyl isononanoate, cyclomethicone and 2-ethylhexyl isostearate are also particularly advantageous.
Die wäßrige Phase der erfindungsgemäßen Zubereitungen enthält gegebenenfalls vorteilhaft Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmonoethyl- oder -mo- nobutylether, Propylenglykolmonomethyl, -monoethyl- oder -monobutylether, Diethy- lenglykolmonomethyl- oder -monoethylether und analoge Produkte, ferner Alkohole niedriger C-Zahl, z.B. Ethanol, Isopropanol, 1 ,2-Propandiol, Glycerin sowie insbesondere ein oder mehrere Verdickungsmittel, welches oder welche vorteilhaft gewählt werden können aus der Gruppe Siliciumdioxid, Aluminiumsilikate.The aqueous phase of the preparations according to the invention advantageously advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethy- glycol monomethyl or monoethyl ether and analog products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide and aluminum silicates.
Erfindungsgemäße als Emulsionen vorliegenden Zubereitungen enthalten insbesondere vorteilhaft ein oder mehrere Hydrocolloide. Diese Hydrocolloide können vorteilhaft gewählt werden aus der Gruppe der Gummen, Polysaccharide, Cellulosederivate, Schichtsilikate, Polyacrylate und/oder anderen Polymeren. Erfindungsgemäße als Hydrogele vorliegenden Zubereitungen enthalten ein oder mehrere Hydrocolloide. Diese Hydrocolloide können vorteilhaft aus der vorgenannten Gruppe gewählt werden.Preparations according to the invention which are present as emulsions particularly advantageously contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the group of the gums, polysaccharides, cellulose derivatives, phyllosilicates, polyacrylates and / or other polymers. Preparations according to the invention which are present as hydrogels contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group.
Zu den Gummen zählt man Pflanzen- oder Baumsäfte, die an der Luft erhärten und Harze bilden oder Extrakte aus Wasserpflanzen. Aus dieser Gruppe können vorteilhaft im Sinne der vorliegenden Erfindung gewählt werden beispielsweise Gummi Arabicum, Johannisbrotmehl, Tragacanth, Karaya, Guar Gummi, Pektin, Gellan Gummi, Carrageen, Agar, Algine, Chondrus, Xanthan Gummi.Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, locust bean gum, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
Weiterhin vorteilhaft ist die Verwendung von derivatisierten Gummen wie z.B. Hydroxypropyl Guar (Jaguar® HP 8).The use of derivatized gums such as e.g. Hydroxypropyl guar (Jaguar® HP 8).
Unter den Polysacchariden und -derivaten befinden sich z.B. Hyaluronsäure, Chitin und Chitosan, Chondroitinsulfate, Stärke und Stärkederivate.Among the polysaccharides and derivatives are e.g. Hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
Unter den Cellulosederivaten befinden sich z.B. Methylcellulose, Carboxymethylcellulose, Hydroxyethylcellulose, Hydroxypropylmethylcellulose.Among the cellulose derivatives are e.g. Methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
Unter den Schichtsilikaten befinden sich natürlich vorkommende und synthetische Tonerden wie z.B. Montmorillonit, Bentonit, Hektorit, Laponit, Magnesiumaluminiumsilikate wie Vee- gum®. Diese können als solche oder in modifizierter Form verwendet werden wie z.B. Stea- rylalkonium Hektorite.Layered silicates contain naturally occurring and synthetic clays such as Montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Vegegum®. These can be used as such or in a modified form such as e.g. Stearylalkonium hectorite.
Weiterhin können vorteilhaft auch Kieselsäuregele verwendet werden.Furthermore, silica gels can also advantageously be used.
Unter den Polyacrylaten befinden sich z.B. Carbopol Typen der Firma Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 oder Pemulen TR2).The polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
Unter den Polymeren befinden sich z.B. Polyacrylamide (Seppigel 305), Polyvinylalkohole, PVP, PVP / VA Copolymere, Polyglycole. Erfindungsgemäße als Emulsionen vorliegenden Zubereitungen enthalten einen oder mehrere Emulgatoren. Diese Emulgatoren können vorteilhaft gewählt werden aus der Gruppe der nichtionischen, anionischen, kationischen oder amphoteren Emulgatoren.The polymers include, for example, polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols. Preparations according to the invention in the form of emulsions contain one or more emulsifiers. These emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
Unter den nichtionischen Emulgatoren befinden sich a) Partialfettsäureester und Fettsäureester mehrwertiger Alkohole und deren ethoxylierte Derivate (z. B. Glycerylmonostearate, Sorbitanstearate, Glycerylstearylcitrate, Sucrose- stearate) b) ethoxylierte Fettaikohole und Fettsäuren c) ethoxilierte Fettamine, Fettsäureamide, Fettsäurealkanolamide d) Alkylphenolpolyglycolether (z.B. Triton X)The nonionic emulsifiers include a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates) b) ethoxylated fatty alcohols and fatty acids c) ethoxylated alcohol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycols e.g. Triton X)
Unter den anionischen Emulgatoren befinden sich a) Seifen (z. B. Natriumstearat) b) Fettalkoholsulfate c) Mono-, Di- und Trialkyiphosphosäureester und deren EthoxylateThe anionic emulsifiers include a) soaps (e.g. sodium stearate) b) fatty alcohol sulfates c) mono-, di- and trialkyiphosphonic acid esters and their ethoxylates
Unter den kationischen Emulgatoren befinden sich a) quaternäre Ammoniumverbindungen mit einem langkettigen aliphatischen Rest z.B. Distearyldimonium ChlorideThe cationic emulsifiers include a) quaternary ammonium compounds with a long-chain aliphatic radical, e.g. Distearyldimonium Chloride
Unter den amphoteren Emulgatoren befinden sich a) Alkylamininoalkancarbonsäuren b) Betaine, Sulfobetaine c) ImidazolinderivateThe amphoteric emulsifiers include a) alkylamininoalkane carboxylic acids b) betaines, sulfobetaines c) imidazoline derivatives
Weiterhin gibt es natürlich vorkommende Emulgatoren, zu denen Bienenwachs, Wollwachs, Lecithin und Sterole gehören.There are also naturally occurring emulsifiers, which include beeswax, wool wax, lecithin and sterols.
O/W-Emulgatoren können beispielsweise vorteilhaft gewählt werden aus der Gruppe der po- lyethoxylierten bzw. polypropoxylierten bzw. polyethoxylierten und polypropoxylierten Produkte, z.B.: der Fettalkoholethoxylate der ethoxylierten Wollwachsalkohole, der Polyethylenglycolether der allgemeinen Formel R-O-(-CH2-CH2-O-)n-R', der Fettsäureethoxylate der allgemeinen FormelO / W emulsifiers can, for example, advantageously be selected from the group of the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example: the fatty alcohol ethoxylates the ethoxylated wool wax alcohols, the polyethylene glycol ethers of the general formula RO - (- CH 2 -CH 2 -O-) n -R ', the fatty acid ethoxylates of the general formula
R-COO-(-CH2-CH2-O-)n -H, der veretherten Fettsäureethoxylate der allgemeinen FormelR-COO - (- CH 2 -CH 2 -O-) n -H, the etherified fatty acid ethoxylates of the general formula
R-COO-(-CH2-CH2-O-)n -R', der veresterten Fettsäureethoxylate der allgemeinen FormelR-COO - (- CH 2 -CH 2 -O-) n -R ', the esterified fatty acid ethoxylates of the general formula
R-COO-(-CH2-CH2-O-)n -C(O)-R', der Polyethylenglycolglycerinfettsäureester der ethoxylierten Sorbitanester der Cholesterinethoxylate der ethoxylierten Triglyceride der Alkylethercarbonsäuren der allgemeinen FormelR-COO - (- CH 2 -CH 2 -O-) n -C (O) -R ', the polyethylene glycol glycerol fatty acid ester of the ethoxylated sorbitan esters of the cholesterol ethoxylates of the ethoxylated triglycerides of the alkyl ether carboxylic acids of the general formula
R-O-(-CH2-CH2-O-)n-CH2-COOH nd n eine Zahl von 5 bis 30 darstellen, der Polyoxyethylensorbitolfettsäureester, der Alkylethersulfate der allgemeinen Formel R-O-(-CH2-CH2-O-)n-SO3-H der Fettalkoholpropoxylate der allgemeinen FormelRO - (- CH 2 -CH 2 -O-) n -CH 2 -COOH and n represent a number from 5 to 30, the polyoxyethylene sorbitol fatty acid esters, the alkyl ether sulfates of the general formula RO - (- CH 2 -CH 2 -O-) n -SO 3 -H of the fatty alcohol propoxylates of the general formula
R-O-(-CH2-CH(CH3)-0-)n-H, der Polypropylenglycolether der allgemeinen FormelRO - (- CH 2 -CH (CH 3 ) -0-) n -H, the polypropylene glycol ether of the general formula
R-O-(-CH2-CH(CH3)-O-)n-R', der propoxylierten Wollwachsalkohole, der veretherten FettsäurepropoxylateRO - (- CH 2 -CH (CH 3 ) -O-) n -R ', the propoxylated wool wax alcohols, the etherified fatty acid propoxylates
R-COO-(-CH2-CH(CH3)-O-)n-R', der veresterten Fettsäurepropoxylate der allgemeinen FormelR-COO - (- CH 2 -CH (CH 3 ) -O-) n -R ', the esterified fatty acid propoxylates of the general formula
R-COO-(-CH2-CH(CH3)-O-)n-C(O)-R', der Fettsäurepropoxylate der allgemeinen FormelR-COO - (- CH 2 -CH (CH 3 ) -O-) n -C (O) -R ', the fatty acid propoxylates of the general formula
R-COO-(-CH2-CH(CH3)-O-)n-H, der Polypropylenglycolglycerinfettsäureester der propoxylierten Sorbitanester der Cholesterinpropoxylate der propoxylierten Triglyceride der Alkylethercarbonsäuren der allgemeinen FormelR-COO - (- CH 2 -CH (CH 3 ) -O-) n -H, the polypropylene glycol glycerol fatty acid ester of the propoxylated sorbitan esters of the cholesterol propoxylates of the propoxylated triglycerides of the alkyl ether carboxylic acids of the general formula
R-O-(-CH2-CH(CH3)O-)n-CH2-COOH der Alkylethersulfate bzw. die diesen Sulfaten zugrundeliegenden Säuren der allgemeinen Formel R-O-(-CH2-CH(CH3)-O-)n-SO3-H der Fettalkoholethoxylate/propoxylate der allgemeinen Formel R-O-Xn-Ym-H, der Polypropylenglycolether der allgemeinen Formel R-O-Xn-Ym-R', der veretherten Fettsäurepropoxylate der allgemeinen Formel R-COO-Xn-Ym-R', der Fettsäureethoxylate/propoxylate der allgemeinen Formel R-COO-Xn-Ym-H,.RO - (- CH 2 -CH (CH 3 ) O-) n -CH 2 -COOH the alkyl ether sulfates or the acids of these sulfates on which the general formula RO - (- CH 2 -CH (CH 3 ) -O-) n -SO 3 -H the fatty alcohol ethoxylates / propoxylates of the general formula ROX n -Y m -H, the Polypropylene glycol ethers of the general formula ROX n -Y m -R ', the etherified fatty acid propoxylates of the general formula R-COO-X n -Y m -R', the fatty acid ethoxylates / propoxylates of the general formula R-COO-X n -Y m -H .
Erfindungsgemäß besonders vorteilhaft werden die eingesetzten polyethoxylierten bzw. polypropoxylierten bzw. polyethoxylierten und polypropoxylierten O/W-Emulgatoren gewählt aus der Gruppe der Substanzen mit HLB-Werten von 11 - 18, ganz besonders vorteilhaft mit mit HLB-Werten von 14,5 - 15,5, sofern die O/W-Emulgatoren gesättigte Reste R und R' aufweisen. Weisen die O/W-Emulgatoren ungesättigte Reste R und/oder R' auf, oder liegen Isoal- kylderivate vor, so kann der bevorzugte HLB-Wert solcher Emulgatoren auch niedriger oder darüber liegen.According to the invention, the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5-15. 5, provided the O / W emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
Es ist von Vorteil, die Fettalkoholethoxylate aus der Gruppe der ethoxylierten Stearylal- kohole, Cetylalkohole, Cetylstearylalkohole (Cetearyialkohole) zu wählen. Insbesondere bevorzugt sind:It is advantageous to choose the fatty alcohol ethoxylates from the group of ethoxylated stearyl alcohols, cetyl alcohols, cetyl stearyl alcohols (cetearyl alcohols). The following are particularly preferred:
Polyethylenglycol(13)stearylether (Steareth-13), Polyethylenglycol(14)stearylether (Steareth- 14), Polyethylenglycol(15)stearylether (Steareth-15), Polyethylenglycol(16)stearylether (Stea- reth-16), Polyethylenglycol(17)stearylether (Steareth-17), Polyethylenglycol(18)stearylether (Steareth-18), Polyethylenglycol(19)stearylether (Steareth-19), Polyethylenglycol(20)stea- rylether (Steareth-20),Polyethylene glycol (13) stearyl ether (steareth-13), polyethylene glycol (14) stearyl ether (steareth-14), polyethylene glycol (15) stearyl ether (steareth-15), polyethylene glycol (16) stearyl ether (steareth-16), polyethylene glycol (17) stearyl ether (steareth-17), polyethylene glycol (18) stearyl ether (steareth-18), polyethylene glycol (19) stearyl ether (steareth-19), polyethylene glycol (20) stearyl ether (steareth-20),
Polyethylenglycol(12)isostearylether (lsosteareth-12), Polyethylenglycol(13)isostearylether (lsosteareth-13), Polyethylenglycol(14)isostearylether (lsosteareth-14), Polyethylenglycol- (15)isostearylether (lsosteareth-15), Polyethylenglycol(16)isostearylether (lsosteareth-16), Polyethylenglycol(17)isostearylether (lsosteareth-17), Polyethylenglycol(18)isostearylether (lsosteareth-18), Polyethylenglycol(19)isostearylether (lsosteareth-19), Polyethylenglycol- (20)isostearylether (lsosteareth-20),Polyethylene glycol (12) isostearyl ether (isosteareth-12), polyethylene glycol (13) isostearyl ether (isosteareth-13), polyethylene glycol (14) isostearyl ether (isosteareth-14), polyethylene glycol (15) isostearyl ether (isosteareth-15), polyethylene glycol (16) (Isosteareth-16), polyethylene glycol (17) isostearyl ether (Isosteareth-17), polyethylene glycol (18) isostearyl ether (isosteareth-18), polyethylene glycol (19) isostearyl ether (isosteareth-19), polyethylene glycol (20) isostearyl ether (isosteareth-20),
Polyethylenglycol(13)cetylether (Ceteth-13), Polyethylenglycol(14)cetylether (Ceteth-14), Polyethylenglycol(15)cetylether (Ceteth-15), Polyethylenglycol(16)cetylether (Ceteth-16), Polyethylenglycoi(17)cetylether (Ceteth-17), Polyethylenglycol(18)cetylether (Ceteth-18), Polyethylenglycol(19)cetylether (Ceteth-19), Polyethylenglycol(20)cetylether (Ceteth-20),Polyethylene glycol (13) cetyl ether (ceteth-13), polyethylene glycol (14) cetyl ether (ceteth-14), polyethylene glycol (15) cetyl ether (ceteth-15), polyethylene glycol (16) cetyl ether (ceteth-16), polyethylene glycol (17) cetyl ether ( Ceteth-17), polyethylene glycol (18) cetyl ether (ceteth-18), polyethylene glycol (19) cetyl ether (ceteth-19), polyethylene glycol (20) cetyl ether (ceteth-20),
Polyethylenglycol(13)isocetylether (lsoceteth-13), Polyethylenglycol(14)isocetylether (Iso- ceteth-14), Polyethylenglycol(15)isocetylether (lsoceteth-15), Polyethylenglycol(16)- isocetylether (lsoceteth-16), Polyethylenglycol(17)isocetylether (lsoceteth-17), Polyethylen- glycol(18)isocetylether (lsoceteth-18), Polyethylenglycol(19)isocetylether (lsoceteth-19), Po- lyethylenglycol(20)isocetylether (lsoceteth-20),Polyethylene glycol (13) isocetyl ether (isoceteth-13), polyethylene glycol (14) isocetyl ether (isoceteth-14), polyethylene glycol (15) isocetyl ether (isoceteth-15), polyethylene glycol (16) - isocetyl ether (isoceteth-16), polyethylene glycol (17 ) isocetyl ether (isoceteth-17), polyethylene glycol (18) isocetyl ether (isoceteth-18), polyethylene glycol (19) isocetyl ether (isoceteth-19), polyethylene glycol (20) isocetyl ether (isoceteth-20),
Polyethylenglycol(12)oleylether (Oleth-12), PolyethyIenglycol(13)oleyIether (Oleth-13), Poly- ethylenglycol(14)oleylether (Oleth-14), Polyethylenglycol(15)oleylether (Oleth-15),Polyethylene glycol (12) oleyl ether (Oleth-12), polyethylene glycol (13) oleyIether (Oleth-13), polyethylene glycol (14) oleyl ether (Oleth-14), polyethylene glycol (15) oleyl ether (Oleth-15),
Polyethylenglycol(12)laurylether (Laureth-12), Polyethylenglycol(12)isolaurylether (Isolau- reth-12).Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolureth-12).
Polyethylenglycol(13)cetylstearylether (Ceteareth-13), Polyethylenglycol(14)cetylstearylether (Ceteareth-14), Polyethylenglycol(15)cetylstearylether (Ceteareth-15), Polyethylenglycol(16)- cetylstearylether (Ceteareth-16), Polyethylenglycol(17)cetylstearylether (Ceteareth-17), Poly- ethylenglycol(18)cetylsteary!ether (Ceteareth-18), Polyethylenglycol(19)cetylstearylether (Ceteareth-19), Polyethylenglycol(20)cetylstearylether (Ceteareth-20),Polyethylene glycol (13) cetyl stearyl ether (ceteareth-13), polyethylene glycol (14) cetyl stearyl ether (ceteareth-14), polyethylene glycol (15) cetyl stearyl ether (ceteareth-15), polyethylene glycol (16) - cetyl stearyl ether (ceteareth-16), polyethylene glycol (Ceteareth-17), polyethylene glycol (18) cetylsteary! Ether (Ceteareth-18), polyethylene glycol (19) cetylstearylether (Ceteareth-19), polyethylene glycol (20) cetylstearylether (Ceteareth-20),
Es ist ferner von Vorteil, die Fettsäureethoxylate aus folgender Gruppe zu wählen:It is also advantageous to choose the fatty acid ethoxylates from the following group:
Polyethylenglycol(20)stearat, Polyethylenglycol(21 )stearat, Polyethylenglycol(22)stearat, Polyethylenglycol(23)stearat, Polyethylenglycol(24)stearat, Polyethylenglycol(25)stearat,Polyethylene glycol (20) stearate, polyethylene glycol (21) stearate, polyethylene glycol (22) stearate, polyethylene glycol (23) stearate, polyethylene glycol (24) stearate, polyethylene glycol (25) stearate,
Polyethylenglycol(12)isostearat, Polyethylenglycol(13)isostearat, Polyethylenglycol(14)iso- stearat, Polyethylenglycol(15)isostearat, Polyethylenglycol(16)isostearat, Polyethylenglycol- (17)isostearat, Polyethylenglycol(18)isostearat, Polyethylenglycol(19)isostearat, Polyethylen- glycol(20)isostearat, Polyethylenglycol(21)isostearat, Polyethylenglycol(22)isostearat, Poly- ethylenglycol(23)isostearat, Polyethylenglycol(24)isostearat, Polyethylenglycol(25)isostearat,Polyethylene glycol (12) isostearate, polyethylene glycol (13) isostearate, polyethylene glycol (14) isostearate, polyethylene glycol (15) isostearate, polyethylene glycol (16) isostearate, polyethylene glycol (17) isostearate, polyethylene glycol (18) isostearate, polyethylene glycol (19) isostearate, polyethylene glycol (20) isostearate, polyethylene glycol (21) isostearate, polyethylene glycol (22) isostearate, polyethylene glycol (23) isostearate, polyethylene glycol (24) isostearate , Polyethylene glycol (25) isostearate,
Polyethylenglycol(12)oleat, Polyethylenglycol(13)oleat, PolyethylengIycol(14)oleat, Polyethy- lenglycol(15)oleat, PolyethylenglycoI(16)oleat, PoIyethylenglycol(17)oleat, Polyethylenglycol- (18)oleat, Polyethylenglycol(19)oleat, Polyethylenglycol(20)oleatPolyethylene glycol (12) oleate, polyethylene glycol (13) oleate, polyethylene glycol (14) oleate, polyethylene glycol (15) oleate, polyethylene glycol (16) oleate, polyethylene glycol (17) oleate, polyethylene glycol (18) oleate, polyethylene glycol (19) oleate , Polyethylene glycol (20) oleate
Als ethoxylierte Alkylethercarbonsäure bzw. deren Salz kann vorteilhaft das Natriumlaureth- 11 -carboxylat verwendet werden.The sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
Als Alkylethersulfat kann Natrium Laureth 1-4 sulfat vorteilhaft verwendet werden.Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
Als ethoxyliertes Cholesterinderivat kann vorteilhaft Polyethylenglycol(30)Cholesteryiether verwendet werden. Auch Polyethylenglycol(25)Sojasterol hat sich bewährt.Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative. Polyethylene glycol (25) soyasterol has also proven itself.
Als ethoxylierte Triglyceride können vorteilhaft die Polyethylenglycol(60) Evening Primrose Glycerides verwendet werden (Evening Primrose = Nachtkerze)Polyethylene glycol (60) evening primrose glycerides can advantageously be used as ethoxylated triglycerides (evening primrose = evening primrose)
Weiterhin ist von Vorteil, die Polyethylenglycolglycerinfettsäureester aus der Gruppe Poly- ethylenglycol(20)glyceryllaurat, Polyethylenglycol(21 )glyceryllaurat, Polyethylenglycol(22)gly- ceryllaurat, Polyethylenglycol(23)glyceryllaurat, Polyethylenglycol(6)glycerylcaprat/caprinat, Polyethylenglycol(20)glyceryloleat, Polyethylenglycol(20)glycerylisostearat, Polyethylengly- col(18)glyceryloleat/cocoat zu wählen.It is also advantageous to use the polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / caprinate 20, glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate / cocoat to choose.
Es ist ebenfalls günstig, die Sorbitanester aus der Gruppe Polyethylenglycol(20)sorbitanmo- nolaurat, Polyethylenglycol(20)sorbitanmonostearat, Polyethylenglycol(20)sorbitanmonoiso- stearat, Polyethylenglycol(20)sorbitanmonopalmitat, Polyethylenglycol(20)sorbitanmonooleat zu wählen.It is also expedient to choose the sorbitan esters from the group consisting of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
Als vorteilhafte W/O-Emulgatoren können eingesetzt werden: Fettalkohole mit 8 bis 30 Kohlenstoffatomen, Monoglycerinester gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkancarbonsäuren einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C- Atomen, Diglycerinester gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkancarbonsäuren einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C-Atomen, Monoglycerinether gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkohole einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C-Atomen, Diglyce- rinether gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkohole einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C-Atomen, Propylenglycolester gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkancarbonsäuren einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C-Atomen sowie Sorbitanester gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkancarbonsäuren einer Kettenlänge von 8 bis 24, insbesondere 12 - 18 C-Atomen.Advantageous W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C. Atoms, diglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms, monoglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, diglycerine ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and / or unbranched Alkanecarboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms and sorbitan esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms.
Insbesondere vorteilhafte W/O-Emulgatoren sind Glycerylmonostearat, Glycerylmonoisostea- rat, Glycerylmonomyristat, Giycerylmonooleat, Diglycerylmonostearat, Diglycerylmonoiso- stearat, Propylenglycolmonostearat, Propylenglycolmonoisostearat, Propylenglycolmonocap- rylat, Propylenglycolmonolaurat, Sorbitanmonoisostearat, Sorbitanmonolaurat, Sorbitanmo- nocaprylat, Sorbitanmonoisooleat, Saccharosedistearat, Cetylalkohol, Stearylalkohol, Arachi- dylalkohol, Behenylalkohol, Isobehenylalkohol, Selachylalkohol, Chimylalkohol, Polyethylen- glycol(2)stearylether (Steareth-2), Glycerylmonolaurat, Glycerylmonocaprinat, Glycerylmono- caprylat.Particularly advantageous W / O emulsifiers are glyceryl Glycerylmonoisostea- advice, stearate glyceryl monomyristate, Giycerylmonooleat, diglyceryl monostearate, Diglycerylmonoiso-, propylene glycol, propylene glycol monoisostearate, Propylenglycolmonocap- triacrylate, propylene glycol, nocaprylat sorbitan, sorbitan Sorbitanmo-, Sorbitanmonoisooleat, sucrose, cetyl alcohol, stearyl alcohol, Arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyceryl monocaprylate.
Die folgenden Beispiele sollen die Erfindung erläutern, aber nicht einschränken. Die Zahlenangaben beziehen sich auf Gew.-%, sofern nichts Anderes angegeben ist. The following examples are intended to illustrate but not limit the invention. The figures relate to% by weight, unless stated otherwise.
1. Beispiele O/W-Creme1. Examples O / W cream
Figure imgf000032_0001
Figure imgf000032_0001
2. Beis iele O/W-Creme2. Examples of O / W cream
Figure imgf000033_0001
Figure imgf000033_0001
3. Beis iele W/O-Emulsionen3. Examples of W / O emulsions
Figure imgf000034_0001
4. Beis iele W/O Emulsionen
Figure imgf000034_0001
4. Examples of W / O emulsions
Figure imgf000035_0001
Figure imgf000035_0001
5. Beis iele H drodispersionen5. Examples of hydrodispersions
Figure imgf000036_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000038_0001

Claims

Patentansprüche: claims:
1. Verwendung von Wogonin zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung, Pflege und Prophylaxe von sensibler Haut und/oder zur Behandlung und Prophylaxe der Symptome einer negativen Veränderung der physiologischen Homeostase der gesunden Haut.1. Use of Wogonin for the production of cosmetic or dermatological preparations for the treatment, care and prophylaxis of sensitive skin and / or for the treatment and prophylaxis of the symptoms of a negative change in the physiological homeostasis of healthy skin.
2. Verwendung nach Anspruch 1 , wobei die Hautschäden und/oder negativen Hautzustände ein oder mehrere Erscheinungsbilder aus der Gruppe defizitäre, sensitive oder hypoaktive Hautzustände oder defizitäre, sensitive oder hypoaktive Zustände von Hautanhangsgebilden entzündliche Hautzustände sowie atopisches Ekzem, polymorphe Lichtdermatose, Psoriasis, Vitiligo empfindliche, juckende oder gereizte Haut Schuppenbildung der Haare darstellen.2. Use according to claim 1, wherein the skin damage and / or negative skin conditions one or more appearances from the group of deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive conditions of skin appendages, inflammatory skin conditions and atopic eczema, polymorphic light dermatosis, psoriasis, vitiligo sensitive , itchy or irritated skin may cause scaling of hair.
3. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß Wogonin in kosmetischen oder dermatologischen Zubereitungen eingesetzt wird, einem Gehalt von 0,0005 - 50,0 Gew.-%, insbesondere 0,01 - 20,0 Gew.-%, entsprechend, bezogen auf das Gesamtgewicht der Zusammensetzung.3. Use according to claim 1, characterized in that wogonin is used in cosmetic or dermatological preparations, a content of 0.0005 - 50.0 wt .-%, in particular 0.01 - 20.0 wt .-%, correspondingly, based on the total weight of the composition.
4. Verwendung nach Anspruch 1 , dadurch gekennzeichnet, daß ein oder mehrere Isoflavone zusammen mit Wogonin eingesetzt werden, einem Gehalt von 0,0005 - 50,0 Gew.- %, insbesondere 0,01 - 20,0 Gew.-%, entsprechend, bezogen auf das Gesamtgewicht der Zusammensetzung.4. Use according to claim 1, characterized in that one or more isoflavones are used together with wogonin, a content of 0.0005 - 50.0% by weight, in particular 0.01 - 20.0% by weight, accordingly , based on the total weight of the composition.
5. Verwendung nach Anspruch 1 , dadurch gekennzeichnet, daß ein oder mehrere Isoflavone zusammen mit Wogonin eingesetzt werden, einem Gehalt des oder der Isoflavone von 0,02 - 10,0 Gew.-%, bevorzugt 0,02 - 5,0 Gew.-%, besonders vorteilhaft 0,5 - 3,0 Gew.-%, entsprechend, jeweils bezogen auf das Gesamtgewicht der Zusammensetzung. 5. Use according to claim 1, characterized in that one or more isoflavones are used together with wogonin, a content of the or the isoflavones of 0.02 - 10.0 wt .-%, preferably 0.02 - 5.0 wt. %, particularly advantageously 0.5-3.0% by weight, correspondingly, in each case based on the total weight of the composition.
PCT/EP2002/008824 2001-08-14 2002-08-07 Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin WO2003015766A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10139793A DE10139793A1 (en) 2001-08-14 2001-08-14 Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and / or for skin protection in the case of sensitive, dry skin
DE10139793.3 2001-08-14

Publications (1)

Publication Number Publication Date
WO2003015766A1 true WO2003015766A1 (en) 2003-02-27

Family

ID=7695342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008824 WO2003015766A1 (en) 2001-08-14 2002-08-07 Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin

Country Status (2)

Country Link
DE (1) DE10139793A1 (en)
WO (1) WO2003015766A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631304A1 (en) * 2003-04-04 2006-03-08 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US8124134B2 (en) 2002-03-22 2012-02-28 Unigen, Inc. Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
US8247007B2 (en) 2006-10-12 2012-08-21 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria
US8652535B2 (en) 2002-04-30 2014-02-18 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US9370544B2 (en) 2002-04-30 2016-06-21 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
CN111655253A (en) * 2018-01-09 2020-09-11 杨百翰大学 Compositions and methods for treating pain with wogonin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07277942A (en) * 1994-04-07 1995-10-24 Osaka Yakuhin Kenkyusho:Kk External preparation for skin
US5466452A (en) * 1991-02-28 1995-11-14 Phytopharm Ltd. Pharmaceutical compositions for the treatment of skin disorders
US5643598A (en) * 1988-03-09 1997-07-01 Lvmh Recherche Method of skin care utilizing liposomes containing Scutellaria extracts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779059B1 (en) * 1998-05-29 2004-09-10 Guerlain COSMETIC TREATMENT PROCESS FOR COMBATING THE EFFECTS OF CUTANEOUS AGING; NEW COSMETIC COMPOSITIONS FOR ITS IMPLEMENTATION
PL187310B1 (en) * 1997-04-29 2004-06-30 Antoni Gwardys Natural antioxidative preparation
WO2001030342A1 (en) * 1999-10-20 2001-05-03 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643598A (en) * 1988-03-09 1997-07-01 Lvmh Recherche Method of skin care utilizing liposomes containing Scutellaria extracts
US5466452A (en) * 1991-02-28 1995-11-14 Phytopharm Ltd. Pharmaceutical compositions for the treatment of skin disorders
JPH07277942A (en) * 1994-04-07 1995-10-24 Osaka Yakuhin Kenkyusho:Kk External preparation for skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199551, Derwent World Patents Index; AN 1995-400874, XP002223567 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535735B2 (en) 2002-03-01 2013-09-17 Unigen, Inc. Identification of free-B-ring flavonoids as potent COX-2 inhibitors
US9061039B2 (en) 2002-03-01 2015-06-23 Unigen, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US9168242B2 (en) 2002-03-22 2015-10-27 Unigen, Inc. Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia
US8568799B2 (en) 2002-03-22 2013-10-29 Unigen, Inc. Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia
US8124134B2 (en) 2002-03-22 2012-02-28 Unigen, Inc. Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
US9655940B2 (en) 2002-04-30 2017-05-23 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
US9370544B2 (en) 2002-04-30 2016-06-21 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
US8652535B2 (en) 2002-04-30 2014-02-18 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US9849152B2 (en) 2002-04-30 2017-12-26 Unigen, Inc. Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
EP1631304A1 (en) * 2003-04-04 2006-03-08 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
EP1631304A4 (en) * 2003-04-04 2007-03-21 Unigen Pharmaceuticals Inc Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
AU2004228021B2 (en) * 2003-04-04 2010-09-02 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US9622964B2 (en) 2003-04-04 2017-04-18 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US9623068B2 (en) 2006-10-12 2017-04-18 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria
US8247007B2 (en) 2006-10-12 2012-08-21 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria
US8771761B2 (en) 2006-10-12 2014-07-08 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria
CN111655253A (en) * 2018-01-09 2020-09-11 杨百翰大学 Compositions and methods for treating pain with wogonin
JP2021510161A (en) * 2018-01-09 2021-04-15 ブリガム・ヤング・ユニバーシティBrigham Young University Compositions and Methods for Treating Pain with Wogonin
EP3737370A4 (en) * 2018-01-09 2021-12-15 Brigham Young University Compositions and methods for treating pain with wogonin
JP7305654B2 (en) 2018-01-09 2023-07-10 ブリガム・ヤング・ユニバーシティ Compositions and methods for treating pain with wogonin

Also Published As

Publication number Publication date
DE10139793A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
DE10356164A1 (en) Active ingredient combinations of licochalcone A or an extract of Radix Clycyrrhizae inflatae, containing licochalcone A, phenoxyethanol and, if desired, glycerol
WO2005053680A1 (en) Combination of 2,3-dibenzylbutyrolactone and licochalcone-a
DE10356187A1 (en) Active substance combinations of phytosterols and / or cholesterol and licochalcone A or an aqueous extract of Radix Glycyrrhizae inflatae, containing licochalcone A.
WO2002102338A1 (en) Carnitine and acyl-carnitines used in the treatment and prophylaxis of pigmentation disorders
EP1367987A2 (en) Use of active-ingredient combinations consisting of alpha-lipoic acid and dermatologically compatible substances that absorb light in the uv-a and/or uv-b wavelength range(s), for producing cosmetic or dermatological preparations
WO2003015766A1 (en) Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin
WO2003015737A1 (en) Use of oroxylin a for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin
DE10218476A1 (en) Medicaments, cosmetics and dermatological compositions for a wide variety of skin treatments contain lignans or their glycosides
EP1395239A1 (en) Cosmetic or dermatological preparations containing one or more ketohexoses
EP1676571A1 (en) Composition comprising at least one isoflavonoid and carnitine and/ or at least one acyl-carnitine
EP1449514A1 (en) Skin care compositions with retinoids, ubiquinones, and biotin or carnitine
DE10140538A1 (en) Cosmetic or dermatological compositions useful for treating inflammatory skin conditions and dry skin comprise a Pongamia pinnata extract
DE10140539A1 (en) Cosmetic or dermatological compositions useful for treating inflammatory skin conditions and dry skin comprise a Terminalia arjuna extract
EP1368026A1 (en) Use of active substance combinations from alpha lipoic acid and substances that absorb light in the uv-a and/or uv-b range for use in the treatment and/or prophylaxis of undesired cutaneous pigmentation
WO2003101407A1 (en) Use of honeysuckle extracts for producing cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for protecting sensitive skin
WO2003015767A2 (en) Use of tectorigenin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin
DE10126396A1 (en) Cosmetic or dermatological preparations containing glucosamine, useful e.g. for treatment, care and prophylaxis of sensitive skin and treatment of inflammatory conditions such as eczema or psoriasis
DE10252772A1 (en) Cosmetic or dermatological composition used for treating e.g. against skin sensitivity, inflammation, psoriasis, pruritis and dandruff contains diethyl dithiocarbamate
DE10148266A1 (en) Mevalonic acid or its lactone is used in cosmetics or dermatological compositions for treating UV skin damage or symptoms of skin-ageing
DE10202251A1 (en) Cosmetic and / or dermatological preparation
DE10224459A1 (en) Cosmetic or dermatological composition contains great burnet extract, effective e.g. against skin sensitivity, irritation or inflammation and immunostimulation in the skin, e.g. for wound treatment
WO2002069911A2 (en) Active substance combination consisting of $g(a)-liponic acid and bioquinones
DE10257949A1 (en) Cosmetic or dermatological preparation for use on sensitive skin in treating e.g. inflammations or wounds contains thiodiglycol
DE10111047A1 (en) Combination used in cosmetics or dermatological compositions to reinforce the skin&#39;s barrier function, comprises lipoic acid and UV absorbers
DE10241889A1 (en) Cosmetic or dermatological compositions, e.g. useful for preventing or treating inflammatory skin conditions, sensitive or dry skin, include a quinolinic acid compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP